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Abstract
MicroRNAs (miRNAs) are short (~ 22 nucleotides long) noncoding RNAs that
regulate gene expression post-transcriptionally. They control the expression of
various genes that are crucial for cellular function, development and human
diseases. Tools to regulate the level and function of miRNAs facilitate the studies
of their functions and have therapeutic applications. In my thesis, I developed a
new customizable miRNA biogenesis inhibitor to regulate miRNAs.
Antisense oligonucleotides (ASOs) have been used to regulate miRNA through
controlling their production or function. Although commonly used due to the fact

v

that they are ease to design, several limitations exist for ASOs including serious
off target effects, low cellular permeability and poor pharmacokinetics and
distribution. To address these limitations, we proposed a new class of ASO based
bi-functional molecules using short ASOs as the pre-miRNA recognition unit linked
to a RNase III inhibitor as a Dicer inhibitor to block miRNA maturation. We showed
the feasibility of the bi-functional strategy and optimized the bi-functional molecules
through enhancing each functional unit as compounds 12, 22 and 25. Additionally,
we identified cell penetrating peptide (CPP) that facilitate the delivery of bifunctional molecules to address the cell permeability issue.
We also explored the feasibility of using cyclic peptidomimetics as an alternative
class of molecule to target RNAs, which can be used as our pre-miRNA recognition
unit in the bi-functional regulator. We identified a new pre-miR-155 binder
(compound 27) that inhibits miR-155 biogenesis. Applying RNAseq and
bioinformatics analysis, we investigated its targeting selectivity and downstream
effects.
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Chapter 1
Introduction
1.1 Biogenesis and regulatory mechanism of miRNAs
Since the first discovery of microRNA (lin4) in 1993 which targets lin-14 gene and
controls the larval development of C. elegans1, more than 15,000 microRNAs
(miRNAs or miR) have been discovered.2 Out of these, more than 2500 are
expressed in human cells and each of these is found to regulate the expression of
numerous protein-coding genes (tens to hundreds). MiRNAs are ~ 21 to 23
nucleotide noncoding single-stranded RNAs (ssRNAs) that have important role in
post transcriptional gene regulation either by mediating transcriptional repression
or by degrading their target mRNAs. Furthermore, these non-coding RNAs play
crucial roles in diverse biological activities such as cell proliferation, differentiation,
metabolism as well as apoptosis3.
There are two pathways for the processing of miRNA genes transcribed from RNA
polymerase II promoters, i.e. canonical and non-canonical pathways. In canonical
pathway, RNA polymerase II transcribes miRNAs as primary miRNA (pri-miRNA)
hairpins, which are further processed by the Drosha-DGCR8 (DiGeorge syndrome
critical region 8) complex to precursor miRNAs (pre-miRNAs).4-6 Pre-miRNAs in
turn transported into the cytoplasm by Exportin 5 and further processed by DicerTRBP (TAR RNA-binding protein 2) and loaded into Argonaute 2 (AGO2) to form
RNA-induced silencing complexes (RISCs) to suppress downstream gene
expression. In non-canonical pathway, pre-miRNAs are derived as the

1

spliceosome-dependent mechanisms bypassing Drosha and the formed premiRNAs are processed by Dicer to give mature miRNAs to be loaded into an RNAinduced silencing complex (RISC) as in the canonical pathway.7,8 RISC loaded

Figure 1.1: miRNA biogenesis and functions3

2

with mature miRNA targets complementary 3’-UTR region of mRNA sequence and
results in the post transcriptional gene silencing either by mRNA degradation or by
translational repression or both, first translational repression followed by mRNA
degradation9-12. (Fig 1.1)
Primarily miRNAs act as post transcriptional gene regulator by targeting mRNA
through base pairing, resulting in either mRNA degradation or translation
repression depending on the extent of complementarity. The mature miRNA strand
loaded within RISC complex, comprises a seed region of miRNA where nucleotide
2-8 precisely match the complementary sequence of 3’-UTR the mRNA to be
targeted. Depending on the extent of base pairing outside the seed region, mRNA
may either undergo degradation or translational repression. For example, perfect
complementarity between miRNA and mRNA (mainly in plant cell) results into
endonuclease mRNA degradation13 whereas imperfect complementarity with

Figure 1.2: Mechanism of miRNA targeting.13
3

some bulges or mismatched regions (mainly in animal cells) results in to
translational repression or followed by mRNA degradation14-17 (Fig 1.2).
Imperfect complementarity between miRNAs and targeted mRNAs can have direct
effects on protein translation by causing the inhibitory action at the various stages
of translation, e.g. repression at the initiation step by blocking the recruitment of
40S and /or 60Sribosomes near the 5’-cap of mRNA, ribosomal drop-off from
mRNA by dissociation 40S/60S ribosomes, by hindering elongation through
blocking ribosomes from joining during elongation process. Additionally, deadenylation of 3’poly-A tail of the mRNA will cause indirect translational repression
resulting in the enhanced mRNA degradation (Fig 1.3).18-31

Figure 1.3: Post-transcriptional gene regulation by miRNAs13
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1.2 Functions of miRNAs and their links to human diseases
MiRNAs play important roles in physiological homeostasis and pathophysiological
conditions in diseases. Some miRNAs are more tissue specific and its expression
level indicates certain pathological or physiological condition of related organs.
Many researchers have found involvement of miRNAs in cell and tissue
development, cancers, cardiovascular system, metabolism, viral infections,
neuropsychiatric disorders etc. (examples in Table 1.1)3,13, 32-54
Involved in

Role

Examples of

miRNAs

involved
Cell and Tissue

•

Development

Proliferation and differentiation of
embryonic stem (ES) cells.

•

Lineage

commitment

during

embryogenesis.

Cancer

•

•

Maturation of multiple tissues.

•

Tumorigenesis and Metastasis

•

Oncogene suppressor

miR-290 cluster
and miR-21

•

miR-133b

•

miR-1, miR-133
and miR-143

•

miR-17-92
cluster
(oncomiR-1) and
miR-10b

•

miR-15a,
16-1,

5

miR-

miR-126,

miR-355,

miR-

200 etc.
Cardiovascular

•

system

Endothelial cell (EC) proliferation

•

and angiogenesis
•

Cardiac function

•

Oxidative stress regulation

Let-7f and miR27b

•

miR-1 and miR133

•

miR-21, miR-221
and miR-222

Metabolism

•

Tissue differentiation (involved in

•

•

•

Regulation of insulin release and

and

miR-29b

energy production, utilization and
storage)

miR-375

miR-122,

miR-

103 and miR-107

metabolism
•

Amino acid and lipid metabolism

Table 1.1: miRNAs in health and diseases

This understanding of cellular mechanisms of regulatory miRNAs and connections
of their dysregulation with so many pathophysiological conditions suggest that
possibility of exploiting miRNAs and their regulator stakeholders as a target to
address and cure multiple pathophysiological conditions or diseases.
6

1.3 Current methods to regulate miRNAs
Several approaches have been developed to regulate the level or activity of
miRNAs is based upon level and activity of mature miRNA, include using miRNA
sponges as an alternative for miRNA targets or using small molecules or
chemically modified antisense oligonucleotides as inhibitors.
miRNA sponge
This technique is based upon the overexpression of a transcript containing several
artificial miRNA binding sites, each of which acts as binding site for endogenous
miRNAs and altogether as sponges. As a result, the expression of target mRNA
remains unaffected. Although this method is useful to investigate the miRNAs
function in vitro, its dependency on cellular machinery to overexpress miRNA
target sites and the requirement of special delivery methods for cellular uptake,
makes it difficult for in vivo studies.55-58
Small molecule inhibitors
Several small molecule-based miRNA inhibitors have been discovered and
developed to control miRNA expression and function. Small molecules act mainly
through regulation on the expression and maturation of targeted miRNAs.
Aminoglycosides have long been regarded as good RNA binders, several of these
aminoglycosides and modified aminoglycosides are reported as miRNA
biogenesis inhibitors.59,60 Xanthone derivatives and other small molecules
incorporating some aromatic and heteroaromatic moieties obtained by screening
a library of small molecules against miRNA precursors have also been reported as
7

efficient miRNA biogenesis as well as functional inhibitors.61-66 Aza-flavones are
also found to be an important class of miRNA inhibitors.67 Although some of the
small molecule inhibitors are found to be effective in regulating miRNA function or
expression, the relatively high EC50 value, the difficulty to design inhibitors based
on target RNA sequences, and the limited understanding about the molecular
mechanisms of inhibition by these molecules pose great challenges in therapeutic
applications of this method.59-67
Antisense oligonucleotides
Antisense oligonucleotide (ASO) technology has been the most commonly used
method for miRNA regulation. One major advantage of using ASOs as oppose to
small molecules is that the sequence-based design of inhibitors can be easily
achieved. Most ASOs are designed to target miRNAs (e.g. anti-miRs) that inhibit
the miRNA function or production by steric disruption of the interaction between
miRNAs or pre-miRNAs and their protein partners (e.g. RNA-induced silencing
complex (RISC) or Dicer), which lead to the inhibition of either their binding to
endogenous mRNA targets or the maturation of miRNAs. Several chemically
modified ASOs have been developed as anti-miRs to enhance their stability and
binding affinity. Modifications like 2’-OMe are resistance to endonuclease,
however, susceptible to degradation by exonuclease, which limits its applications.
Phosphorothioate modification converting a non-bridging oxygen atom into sulfur
offers an excellent exonuclease resistance and better cellular uptake. Mixed
oligonucleotides with both 2’-OMe and phosphorothioate modifications have been
used commonly as anti-miRs. Additionally, modifications like 2’-fluoro (2’-F), 2’8

Figure 1.4: miRNA regulation strategies3

methoxyethyl (2’-MOE) and locked nucleic acid (LNA) are also used to improve
nuclease resistance while maintaining strong DNA/RNA binding affinity (Fig 1.5).
These modifications can be used alone or mixed to tune the efficiency of anti-miRs.
Backbone modifications (MO, PNA), although being used widely, these ASOs
9

typically have problem with cellular delivery, special methods are required to
deliver these ASOs into cells.3

Figure 1.5: Chemically modified nucleotides83

Most of these ASOs act through competing with strong macromolecular interaction
between miRNAs and their binding proteins. To offer effective competition, long
ASOs are typically used (e.g. 25 nucleotides in case of MOs). Despite of
consistency and efficacy, using long ASOs usually lead to off-target binding to
other miRNAs, mRNA and other cellular RNAs.
Although with longer ASOs, we supposed to have fewer perfectly matched targets
in the transcriptome, under physiological conditions, each ASO can interact with
any RNAs through imperfect base pairing similar to non-specific priming observed
in PCR at low annealing temperatures. As a result, small interfering RNA (siRNA)
and miRNA mimetic including LNA and antagomirs have been shown to give
10

unwanted off-target effects.68-82 Such imperfect pairing is used by miRNA to
regulate up to hundreds of mRNAs in the cells. Besides off-target inhibition, current
ASOs cannot be used to dissect differential functions among miRNAs of same
family (with similar mature sequence), along with the poor cellular delivery and
distribution limit the utility of this strategy.
To address the issues of current ASO methods, my thesis is focused on the design
and development of a new class of bi-functional miRNA regulators with distinct
chemical structures and inhibitory mechanisms.

11
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Chapter 2
Developing ASO-based bi-functional miRNA regulators
2.1 Introduction
We designed a unique class of bi-functional miRNA regulators that blocks the
Dicer-mediated maturation of miRNAs. Since Dicer knockdown causes serious
biological defects including cell toxicity,4,5 the bi-functiuonal molecules were
designed to block the Dicer activity by selectively inhibiting the catalytic turnover
of unique Dicer-pre-miRNA complexes to block the maturation of miRNA of
interest. Dicer is a member of the ribonuclease III family that processes stem-loop
double stranded pre-miRNAs (~ 70 nts) into mature miRNAs.

Figure 2.1: Downregulation of a specific miRNA through inhibiting its pre-miRNA cleavage
by Dicer. (A bi-functional miRNA regulator selectively binds to the loop sequence of targeted premiRNA (red) and is brought to the associated Dicer. The inhibitor module in the regulator blocks
the pre-miRNA cleavage by Dicer only at the targeted pre-miRNA.)
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The designed bi-functional miRNA regulators contain a low affinity Dicer inhibitor
covalently linked to a high affinity sequence-specific pre-miRNA recognition
molecule to recognize and inhibit only specific Dicer molecules that would catalyze
the cleavage of a specific pre-miRNA. At low concentrations, the weak binding
Dicer inhibitor cannot inhibit Dicer activity on its own so that Dicer cellular function
will remain intact. When bi-functional regulators bind to the loop region of targeted
pre-miRNAs, the Dicer inhibitor will be placed at the active site of specific Dicer,
with a dramatically increased local effective concentration of the Dicer inhibitor to
achieve Dicer inhibition. There are many reported RNase III inhibitors that can
potentially be used as our low affinity Dicer inhibitor through a two divalent metal
ion catalyzed mechanism1-3 with IC50 ranging from low to high µM concentration.6,7
Commercial custom synthesized morpholino oligonucleotides can were used as
the high affinity pre-miRNA recognition module. MOs have standard nucleic acid
bases

linked

to

a

morpholine

rings

connected

phosphorodiamidates

instead

through
of

uncharged

phosphodiester

linkages (Figure 2.2), which gives the better binding
affinity to RNAs as well as better nuclease resistance813.

As oppose to the standard long MOs (25-mer/

commonly used, we incorporated a short version of
Figure 2.2 Morpholino12

MOs 14-mer or less) to target the pre-miRNA loop
region. We hypothesis that individual Dicer inhibitor

unit and the pre-miRNA recognition unit by itself would not be inhibitory unless
being coupled together to form the bifunctional regulator.
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The function of miRNAs is usually dynamic and cellular context dependent. To
achieve spatiotemporal regulation of miRNAs, we also developed light controllable
bi-functional miRNA regulators. ASOs such as morpholinos have poor cell
permeability and enhanced stability in cells. They cannot get in the cell readily, and
once delivered into the cells, the inhibitory effect of ASOs can be long lasting. To
offer a spatiotemporally inactivatable miRNA regulator, we designed a light
deactivatable version of bi-functional regulator by connecting the pre-miRNA
recognition unit with the Dicer inhibition unit through a photo-cleavable linker. Once
cleaved by light the bifunctional molecule will be fragmented into two inactive units
and the inhibitory effects reversed.

Figure 2.3: Design of light controllable bifunctional molecules

Furthermore, a light activatable bi-functional regulator can be generated by
masking the Dicer inhibition unit with a photo-cleavable caging group. Such
regulators will remain inactive until the caging group is removed by a specific
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radiation of light to release the active bi-functional miRNA regulator. By combining
both of these light activation and inactivation strategies, a bi-functional miRNA
regulator with precise spatiotemporal control can be created (Figure 2.3).
2.2 Results and discussions
Recognition module
To start our investigation about the bi-functional strategy, we choose to use MO as
our pre-miRNA recognition unit, which is designed to be complementary to the
single stranded hairpin loop region of pre-miRNA of interest. This will facilitate the
targeting of exposed sequences and avoid the binding competition with Dicer at
the Dicer cleavage site in the double stranded region. 25-mer MOs (Tm ~ 90°C)14
are currently used to provide the desired knockdown effects, which cause off target
inhibitions under physiological condition likely due to imperfect pairing to many
RNA species in cells. To address this, we used shorter 14-mer MOs (Tm ~60°C)14
as the pre-miRNA recognition unit, which we expect to have reduced off targets
and still form sufficiently stable duplex with pre-miRNAs in cells. Since MOs longer
than 15-mer have been found to have observable biological effects, 14-mer MO
(or shorter) should not block Dicer-mediated pre-miRNA processing by itself.
To investigate if a 14-mer MO is sufficient to specifically match a unique premiRNA in sequence, we performed a BLAST analysis using 14-mer sequences
chosen from the hairpin-loop region of miRNAs associated with human diseases.
Among all the tested sequences, each only matches one unique pre-miRNA.
Although many of these sequences also exist in mRNAs (Figure 2.4), our unique
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bi-functional design, which exerts effects through Dicer enzymatic inactivation
instead of steric interference, minimizes the interference on mRNAs.

Figure 2.4: BLAST analysis of 14-mer pre-miRNAs loop sequences

We have chosen miRNA-21 as our initial target for the study, which was first
identified in 2005 as the most commonly and highly upregulated miRNA in human
brain tumor glioblastoma15. Since then many researchers studied about this miR21 in various fields including oncology, stem cell and aging biology and
development, making it one of the most studied miRNAs (Table 2.1).

Disease cells

miR-21

Biological process

expression
Glioblastoma

Up-regulation

miR-21
targets

Invasion and cell growth

PDCD4,
RECK,
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TIMP3,
NFIB,
APAF1,
STAT3
Breast cancer

Up-regulation

Cell growth, apoptosis,

PDCD4,

angiogenesis and invasion

TPM1,
Maspin

Lung cancer

Up-regulation

Pancreas cancer

Up-regulation

Ovarian cancer

Up-regulation

Cervical cancer

Up-regulation

Colorectal cancer

Up-regulation

Cellular outgrowth, migration,

PDCD4,

invasion and metastasis

NFIB,
SPRY2

Hepatocellular

Up-regulation

carcinoma
Stomach/gastric

Cell migration and invasion and

PTEN

proliferation
Up-regulation

RECK

cancer
Prostate cancer

Up-regulation

Thyroid carcinoma

Up-regulation
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Leukemia

Up-regulation

B-cell and Hodgkin

Up-regulation

lymphoma
Cardiovascular

Up/down

Vascular smooth muscle cell

PDCD4,

regulation

proliferation and apoptosis,

PTEN,

cardiac cell growth and death,

SPRY1,

and cardiac fibroblast functions

SPRY2

Table 2.1: miR-21 regulation and function in human diseases15-21

Figure 2.5: Hair-pin secondary structure of hsa-pre-miR-2122-25 (yellow highlighted region is
the sequence we want to target through our recognition module i.e. MO)

Based upon the sequence of hsa-premiR-21 (Figure 2.5), we have designed the
following MOs with a 3’-azido group, which can be custom synthesized
(GeneTools, Philomath, OR), to be used as our pre-miR-21 recognition unit,
5’-CCATGAGATTCAACAG-3’

(16-mer MO-21)

5’-CCATGAGATTCAACA-3’

(15-mer MO-21)

5’-CATGAGATTCAACA-3’

(14-mer MO-21)
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5’-TGAGATTCAACA-3’

(12-mer MO-21)

5’-AGATTCAACA-3’

(10-mer MO-21)

Furthermore, we used a 25-mer MO-21 (as below) designed by GeneTools as
miR-21 inhibitor, which is complementary to both mature strand sequence and part
of the loop region as a positive control.
AGTCAACATCAGTCTGATAAGCTAC

(25-mer MO-21)

Comparison of off-target binding of 14-mer versus 25-mer MO against
cellular RNAs in vitro
We expect that under physiological temperature, a 25-mer MO will likely target a
lot more different mRNAs through imperfect pairing than a 14-mer, which is a
potential source of causing unwanted biological effects.
To test if a 14-mer MO indeed
recognize less RNAs in the
transcriptome, we got biotinlabeled 14-mer and 25-mer
MOs for recognizing pre-miR21 by click chemistry between
Figure 2.6: Numbers of pulled-down mRNAs by
biotinylated 14-mer and 25-mer MOs designed for
miR-21

the azido-MOs and an alkynegroup attached biotin. These

MOs were incubated separately with total mRNAs purified (using Oligotex mRNAs
kit from QIAGEN, Hilden, Germany) from HeLa cells (known to express miR-21)
at 37°C and the bound RNA species were pull-downed by streptavidin beads. We
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had also incubated biotin only (without MO) with these RNAs as a negative control.
After washing, the bound RNAs with beads were eluted and submitted for RNAseq (using Illumina NextSeq 500 for pair-end sequencing 75bp X 2, 130 million
read). As an indication of the number of RNAs each molecule target, we focused
on mRNAs being pulled down in each condition. Obtained reads were aligned
against human reference genome, annotated and counted. After removing
common RNAs found in biotin-only pull down, we found that the 14-mer MO indeed
bound much less mRNAs than 25-mer MO (Figure 2.6).
Inhibitor and bifunctional molecules
To generate a bi-functional regulator, we chose to use reported N-substituted
Phthalimides (-OH, -OMe, -NH2) (e.g. compound 1, 2 and 3, Figure 2.7) as our
Dicer inhibition unit, which have been reported to inhibit RNase III family enzymes
by chelating two divalent metal ions (Mg2+ in Dicer) in the active site, although
rather poorly (IC50 > 500 µM).6 Furthermore, some other more potent RNase III
inhibitors (low µM) e.g. N-hydroxyimides, diketobutanoates or flutimides
(compound 4, 5 and 6, Figure 2.7)6,7 can also be used.

1, 2 and 3 (R = OH, OMe and NH2)

4

Figure 2.7: Some examples of RNase III inhibitors6,7.
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5

6

We expect that the length and the structure of linkers may also play a crucial role
in the bi-functional molecules activity in addition to the Dicer inhibition unit and the
pre-miRNA recognition unit. As a result, we synthesized and tested several bifunctional miR-21 regulators with different linkers to connect the two functional

Scheme 2.1: Synthesis of bi-functional miRNA regulators with different linker length

units.
To synthesize bi-functional regulators, we synthesized alkyne-equipped Nsubstituted phthalimides (-OH, -OMe, -NH2) (compound 1, 2 and 3) that were
subsequently linked to azido-MOs custom synthesized for pre-miR-21 through
copper catalyzed click chemistry26 (compound 10 to 13) (Scheme 2.1). To test the
importance of the distance between the Dicer inhibition unit and the pre-miRNA
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recognition unit, we synthesized another bi-functional molecule with longer linker
(21 atoms vs. 10 atoms) to connect the two functional units as shown in Scheme
2.1 (Compound 14).
All synthesized molecules were purified by HPLC or silica gel chromatography and
fully characterized before biological assays to ensure the purity (without the
contamination of other organic solvents or reagents that were used during
synthesis). Using click chemistry to assemble the bi-functional molecules will
enable us to generate the new bi-functional regulators for other miRNAs by
switching the pre-miRNA recognition units with MOs designed for other pre-miRNA
sequences.
Stability of bifunctional molecules
To test the stability of the bi-functional molecule, we incubated compound 12 in the
HEPES buffer (pH 7.4, physiological condition) for up to 5 d and phosphate buffer
(pH 6, endosome release condition27) for up to 48 h and then analyzed by HPLC.
We found that the synthesized bi-functional regulator is chemically stable during

Figure 2.8: Chemical stability of the bi-functional regulator by HPLC at different pH
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tested period based on the finding that the peak corresponding to compound 12 in
HPLC chromatogram did not change after the incubation (Figure 2.8).
To further explore the binding of our pre-miR-21 recognition units (i.e. MOs) with
pre-miR-21, gel shift assay was performed. All the recognition units, the
bifunctional molecule (12), or the positive control (25MO-miR-21) and negative
control (25MO-miR-29b1) were incubated with P32-internally labelled premiR-21
at 37 °C for 1.5 h and then subjected to 15% non-denaturing polyacrylamide gel
analysis, followed by exposure to photographic plate and imaging using PMI 1
(Figure 2.9). Gel shift assays showed 14-mer MO (or longer), as well as the bifunctional molecule, stably bound to pre-miR-21 whereas 12-mer MO or 25-mer
MO designed for another pre-miRNA did not bind pre-miR-21. These results
confirm that the 14-mer MO is sufficient to
recognize target pre-miRNA.
Dicer cleavage inhibition assay of bifunctional
molecules
Our bi-functional miRNA regulators are designed
to inhibit Dicer processing of pre-miRNA. To
evaluate Dicer activity on pre-miRNA processing,
Figure 2.9: Gel shift assay for we developed an in vitro assay that includes the
recognition
modules
and
bifunctional molecule (12)

recombinant

Genlantis, San Diego, CA) and

32P-labeled

human

Dicer

proteins

(from

pre-miRNA (produced by the in vitro

transcription from DNA template with T7 promoter using T7 RNA polymerase). By
using this method, we can successfully examine Dicer-mediated processing of pre33

miRNAs (e.g. pre-miR-21) (~ 70 nts) into short mature miRNA (~22 bps) using 16%
denaturing polyacrylamide gel electrophoresis with Decade marker system
(Thermo Fisher Scientific) followed by exposure to photographic plate and imaging
using PMI1 (Figure 2.10).
We then used this assay to test
the

activity

regulators,

of

bi-functional

different

MO,

inhibition units and the control 25mer MO against Dicer-mediate
processing of pre-miR-21, We
found that none of the recognition
Figure 2.10: Dicer-mediated pre-miRNA
cleavage

units

significantly

inhibit

the

processing (up to 100 µM, Figure 2.11). Similarly, none of the synthesized Dicer
inhibition units (compound 7 to 9 up to 1mM) inhibit the processing. In this figure,
25 MO (C) is the scrambled negative control 25-mer MO designed by Gene-Tools
(Figure 2.12). On the contrary, the bi-functional miR-21 regulator with 14-mer MO
(compound 12) blocked the Dicer-mediated pre-miR-21 cleavage process at 10
μM and above, showing a potency improvement of at least 100 folds as compared
to its corresponding inhibition unit (compound 7) (Figure 2.13). Interestingly, the
bi-functional regulator with the longer flexible linker (compound 14), showed a
much lower activity as compared to compound 12 (Figure 2.13).
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Figure 2.11: Dicer cleavage assay for recognition units A) Gel electrophoresis of cleaved
and un-cleaved pre-miR-21 B) quantification of pre-miR-21 band in each lane (3-independent
experiments were used to calculate the error bar)

Figure 2.12: Dicer cleavage assay for inhibition units A) Gel electrophoresis of cleaved and
un-cleaved pre-miR-21 B) quantification of pre-miR-21 band in each lane (3-independent
experiments were used to calculate the error bar)
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Figure 2.13: Dicer cleavage assay for bifunctional molecules A) Gel electrophoresis of
cleaved and un-cleaved pre-miR-21 B) quantification of pre-miR-21 band in each lane (3independent experiments were used to calculate the error bar)

This suggests that the importance of linker in our bi-functional molecule and the
decreased activity may due to the entropic penalty introduced by using a longer
and flexible linker. Encouragingly, bi-functional regulator with the short linker
(compound 12) showed a better activity than the 25-mer MO control at the similar
concentration (Figure 2.13). Overall, we showed that the bi-functional design can
give functional regulators to block miRNA maturation. The 14-mer MO can give
sufficient recognition without inhibiting the process by itself. The linker plays an
important role in the activity. To further explore, the effects of the MO length in the
activity of bi-functional molecules, we synthesized bi-functional molecules with
shorter or longer MOs range from 10-16-mer (Scheme 2.1) and tested their activity
to block miRNA maturation in vitro.
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From the results, we found that bi-functional regulators with MOs shorter than 14mer (compound 10 and 11) have decreasing activity corresponding to the MO
length (Figure 2.14A). Surprisingly, compound 13 (with 16-mer MO) has
decreased activity when compared to compound 12 (with 14-mer MO) (Figure
2.13B). These results suggest that the pre-miRNA recognition unit plays a key role
in the activity of the bi-functional regulator.

Figure 2.14: Dicer cleavage assay for different length recognition unit bifunctional
molecules A) and B) Gel electrophoresis of cleaved and un-cleaved pre-miR-21 C) and D)
quantification of pre-miR-21 band in each lane (3- independent experiments were used to calculate
the error bar) for A and B respectively
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Generating bi-functional regulators for other miRNAs
Based on the findings shown above, we hypothesize that new bi-functional
regulators can be generated to target other miRNAs by swapping the pre-miRNA
recognition unit. To test this, we synthesized bi-functional regulators for hsa-miR29s by replacing the MO unit in the bi-functional miR-21 regulators with an MO
designed to target the loop sequence of pre-miR-29b-1. There are four hsa-miR29, namely hsa-miR-29a, hsa-miR-29b-1, hsa-miR29b-2 and hsa-miR-29c in the
family. Out of four members, miR-29a, miR-29b1 and miR-29c are the most
abundant and functionally important miRNAs.1,28-37
hsa-pre-mir-29a
5’AUGACUGAUUUCUUUUGGUGUUCAGAGUCAAUAUAAUUUUCUAGCACCA
UCUGAAAUCGGUUAU 3’
hsa-pre-mir-29b-1
5’CUUCAGGAAGCUGGUUUCAUAUGGUGGUUUAGAUUUAAAUAGUGAUUG
UCUAGCACCAUUUGAAAUCAGUGUUCUUGGGGG 3’
hsa-pre-mir-29c
5’AUCUCUUACACAGGCUGACCGAUUUCUCCUGGUGUUCAGAGUCUGUUU
UUGUCUAGCACCAUUUGAAAUCGGUUAUGAUGUAGGGGGA 3’
Figure 2.15: Nucleotide sequence of hsa-pre-miR-29 family (The yellow highlighted regions
represent the loop-sequences, green regions represent the 3p-mature sequences and pink regions
represent the less abundant 5p-mature sequences)
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MiR-29 family members share almost identical mature sequences but each has
unique loop sequence among others (Figure 2.16). It is known that miR-29a and
miR-29b-1 are both expressed in Hela cells. However, miR-29a resides in
cytoplasm and miR-29b-1 is transported to the nucleus.38 They also have different

Figure 2.16: Sequence alignment of mature and loop sequences of different hsa-miR29s (black highlighted nucleotides represents the similar sequence)

half-life during cell cycles.38 It suggests that miRNAs within the same family
potentially have different functions.
Since the majority of miRNA genes (~ 70 %) are reported to be grouped into
miRNA families, it is very important to dissect the function of each member in a
family. Current miRNA regulators cannot selectively target individual members
within the same family because most of these techniques target the highly
homologous mature miRNA sequence shared by miRNAs in the same family. Our
bi-functional miRNA regulators targeting the unique loop sequences might be an
efficient way to distinguish individual miRNAs in a family.
To develop a new regulator for miR-29b1 from the bi-functional miR-21 regulator,
we designed our recognition unit (a 3’-azido14-mer MO) to be complementary to
the loop region of pre-miR-29b-1. We also obtained the 25-mer MO antagomir from
Gene tools as a control.8-12
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5’-AACACTGATTTCAAATGGTGCTAGA-3’

(25-mer MO-29b1 antagomir)

5’-ACAATCACTATTTA-3’

(14-mer MO-29b1)

We synthesized the bi-functional regulator (compound 15) by clicking the azido 14mer MO for miR-29b-1 and inhibition unit (compound 7) and tested its activity using
the Dicer cleavage assay.

Figure 2.17: Dicer cleavage assay for pre- miR-29b1 A) and B) Gel electrophoresis of cleaved
and un-cleaved pre-miR-29b1 C) and D) quantification of pre-miR-29b1 band in each lane (3independent experiments were used to calculate the error bar) for A and B respectively

We observed that compound 15 can completely inhibit the processing of pre-miR29b-1 by Dicer and is more potent than the 25-mer MO control at the same
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concentration (Figure 2.17). These results indicate that new bi-functional miRNA
regulators can be quickly generated by switching the pre-miRNA recognition units.
Design and synthesis of light controllable bifunctional molecule
To develop a light controllable version of bi-functional regulators to achieve
spatiotemporal control, we incorporated a photo-cleavable 4, 5-dimethoxy-2nitrobenzyl (DMNB) group (cleavable by 365nm light) in to the linker connecting
the inhibition unit and the recognition unit (compound 16). This will allow a rapid
light inactivation of the bi-functional molecules by separating the two functional
units. We also synthesized the corresponding bi-functional molecule (compound
17) by clicking the azido 14-mer MO to compound 16. Furthermore, to achieve light
activation, it is possible to attach a photo-cleavable [7-diethylaminocoumarin-4-yl]
methyl (DEACM) group to the inhibitor unit at the N-hydroxy group (e.g. compound
18) that can be removed by the 405nm light.39-49

Scheme 2.2: Synthesis of light-controllable bi-functional regulator
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Test the light cleavage efficiency and inactivation of bi-functional molecule
To test the light induced cleavage, we illuminated the synthesized light-controllable
molecule (compound 16) with 365 nm light for different time periods and did HPLC
analysis. We found that the DMNB group on compound 16 can be efficiently
cleaved by 365 nm light (Figure 2.18).
To test if the light irradiated DMNB-containing bi-functional regulator can be
inactivated, we compared the inhibitory activity of compound 16 before and after
365nm light irradiation (10 min) using the Dicer cleavage assay. We observed that
the activity of the light controllable bi-functional molecule (compound 16) was
abolished after light irradiation (Figure 2.19).

Figure 2.18: HPLC analysis cleavage efficiency of compound 16 by using 365 nm light
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Figure 2.19: Dicer cleavage assay for active vs deactivated light controllable bifunctional molecule A) Gel electrophoresis of cleaved and un-cleaved pre-miR-21 B)
quantification of pre-miR-21 band in each lane (3-independent experiments were used to calculate
the error bar)

Facilitating cellular delivery of bi-functional regulators
One of the main problems associated with antisense strategy is the cellular
delivery. One common method used to deliver MO is the use of a delivery agent
‘Endo-porter” (designed by Gene-tools).50-53 To test the cellular delivery efficiency,
we synthesized a model bi-functional regulator with a 14-mer MO and a fluorescent
probe (compound 19) (Scheme 2.3).

Scheme 2.3: Synthesis of the fluorescent bi-functional MO probe.
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We tested the delivery of compound 19 (10 µM) into Hela cells using Endo-Porter
following vendor’s protocol and observed the fluorescence signal under a
fluorescence microscope in presence of Endo-porter. We did observe the delivery
of the model molecule inside the cells although the level was very low and not very
efficient (it took about 72h before a fluorescence signal can be observed in the
cell) (Figure 2.20).
We then tested using Endo-porter to deliver the bi-functional miR-21 regulator
(compound 12) into HeLa cells and examined the changes of the cellular miR-21
level with or without the treatment of the regulator. Unfortunately, no significant
cellular activity was observed by RT-qPCR (monitoring miR-21 levels) and western
blot analysis (monitoring PDCD4 levels, a miR-21 target). The lack of cellular
activity is likely due to the ineffective delivery method, or insufficient activity. In the
next part of my work, I am focusing on optimizing the bi-functional regulators,
including the delivery methods.

Figure 2.20: Cell uptake of the fluorescent bi-functional MO probe (compound 19) in Hela
cells (A= none, B= fluorophore compound only, C= compound 19 only and D= compound 19 +
Endo-porter) after 72 hrs.
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2.3 Conclusion
In this Chapter, we described the design and development of a unique class of bifunctional regulators. We showed that the bi-functional strategy improves the
activity of individual Dicer inhibition and pre-miRNA recognition units. We identified
compound 12 the most potent bi-functional molecule.
Furthermore, with the intention to develop spatiotemporally controlled miRNA
regulation tools, we converted compound 12 into light controllable molecule by
incorporating a light cleavable group in its linker to make it become light
inactivatable (compound 17).
Additionally, the current delivery method, Endo-porter, is found to be inefficient to
deliver our bi-functional molecules and new delivery methods are required.
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2.4 Methods
Bifunctional molecules synthesis

Compound 2 was synthesis as described in the literature 1.
1-Hexynoic acid (1.2 g; 11.24 mmol) and BOP reagent (5.7 g; 13 mmol) were
dissolved in CH2Cl2 (15 mL). After 10 min, 2, 2’-(Ethylenedioxy) diethylamine (10
g; 67.47 mmol) in CH2Cl2 (60 mL) was added. The mixture was stirred at room
temperature for 3 hours. A saturated NaHCO3 aqueous solution (pH 9, 50 mL)
was added and organic layer was extracted several times by CH2Cl2 (50 mL). The
organic phase was filtered, dried with Na2SO4 and evaporated under reduced
pressure. The residue was purified by silica gel column chromatography
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(CH2Cl2/MeOH/Triethylamine, 95/5/0.1) to provide 2 g of (2) (yield 73 %) as a
yellow oil. Rf: 0.31 (CH2Cl2/MeOH/Triethylamine, 9/1/0.1).
Compound 4 was made from compound 3 follow the routine methods.
Compound 5
Propargylamine (55 mg, 1 mmol) was dropped into a solution containing
Compound 4 (211 mg, 1 mmol) in dry THF under ice bath. Followed by Et3N (121
mg, 1.2 mmol). Continue stir 3 hours. Remove the solvent under 30 °C. NH2NH2
(70 mg, 1 mmol) and pyridine (20 mL) were added to the flask and stirred 15 h at
90 °C. Then remove the solvent, wash with water and dry it. Yield: 68 %. 1H NMR
(DMSO-d6, 300 MHz): 11.66 (bs, 2H), 9.39 (t, J= 10.8 Hz, 1H), 8.57 (s, 1H), 8.318.28 (dd, J= 8.4, 1.8 Hz, 1H), 8.14-8.11 (d, J= 8.1 Hz, 1H), 4.11-4.08 (q, J= 7.8 Hz,
2H), 3.17-3.15 (t, J= 4.8 Hz, 1H). 13C NMR (DMSO-d6, 75 MHz): 164.80, 137.13,
131.21, 128.76, 127.42, 125.54, 124.45, 80.98, 73.07, 28.80. TOF-HRMS (m/z)
found (calcd.) for C12H9N3O3 (M): [M+H]+, 244.0721 (244.0722).
Compound 6
Propargylamine (55 mg, 1 mmol) was dropped into a solution containing
Compound 4 (211 mg, 1 mmol) in dry THF under ice bath. Followed by Et3N (121
mg, 1.2 mmol). Continue stir 3 hours. Remove the solvent under 30 °C.
NH2OCH3/HCl (84 mg, 1 mmol) and pyridine (20 mL) were added to the flask and
stirred 15h at 90 °C. Then remove the solvent and purify on silica gel. Yield: 75 %.
1H NMR (DMSO-d6, 300 MHz): 9.34-9.30 (t, J= 10.8 Hz, 1H), 8.30-8.26 (m, 2H),
7.96-7.94 (dd, J= 7.8, 0.6 Hz, 1H), 4.11-4.09 (q, J= 7.8 Hz, 2H), 3.97 (s, 3H), 3.1947

3.18 (t, J= 4.8 Hz, 1H). 13C NMR (DMSO-d6, 75 MHz): 164.03, 162.37, 162.30,
139.09, 133.87, 130.95, 128.99, 123.43, 121.55, 80.74, 73.25, 65.42, 28.83. TOFHRMS (m/z) found (calcd.) for C13H10N2O4 (M): [M+H]+, 259.0710 (259.0719);
[2M+Na]+, 539.1189 (539.1179).
Compound 7
Propargylamine (55 mg, 1 mmol) was dropped into a solution containing
Compound 4 (211 mg, 1 mmol) in dry THF under ice bath. Followed by Et3N (121
mg, 1.2 mmol). Continue stir 3 hours. Remove the solvent under 30 °C.
NH2OH/HCl (70 mg, 1 mmol) and pyridine (20 mL) were added to the flask and
stirred 15 h at 90 °C. Then remove the solvent and purify on silica gel. Yield:75 %.
1H NMR (DMSO-d6, 300 MHz): 10.93 (s, 1H), 9.34-9.30 (t, J= 10.8 Hz, 1H), 8.298.25 (m, 2H), 7.95-7.92 (d, J= 7.5 Hz, 1H), 4.11-4.08 (q, J= 7.8 Hz, 2H), 3.17-3.16
(t, J= 5.1 Hz, 1H). 13C NMR (DMSO-d6, 75 MHz): 164.15, 163.53, 163.46, 138.97,
133.65, 131.068, 129.11, 123.16, 121.31, 80.73, 73.21, 28.78. TOF-HRMS (m/z)
found (calcd.) for C12H8N2O4 (M): [M+H]+, 245.0560 (245.0562).
Compound 8
Copper (I) iodide (50 nmol), Sodium Ascorbate (VcNa) (100 nmol) and Tris[(1benzyl-1H-1,2,3-triazol-4-yl) methyl] amine (50 nmol) were mixed together in
DMSO. Followed by Morpholinos (50 nmol) in water, small molecule (100 nmol) in
DMSO. The mixture was shacked and incubated 15h. Separate on HPLC.
8a: MS (modify protein way) (m/z) found (calcd.): 3843.8 (3844.1).
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8b: MS (modify protein way) (m/z) found (calcd.): 4529.9 (4529.1).
8c: MS (modify protein way) (m/z) found (calcd.): 5183.8. (5184.1).
8d: MS (modify protein way) (m/z) found (calcd.): 5501.5 (5501.1).
8e: MS (modify protein way) (m/z) found (calcd.): 5856.8 (5857.1).
Compound 9
Compound 9 was synthesized follow the method as described for compound 7.
Yield: 35 %.
1H NMR (MeOD, 300 MHz): 8.27-8.25 (m, 2H), 7.95-7.92 (d, J= 7.8 Hz, 1H), 3.713.63 (m, 8H), 3.58-3.54 (t, J= 10.5 Hz, 2H), 3.37-3.33 (t, J= 12.9 Hz, 2H), 2.332.28 (t, J= 14.7 Hz, 2H), 2.24-2.18 (m, 3H), 1.83-1.74 (m, 2H). 13C NMR (MeOD,
75 MHz): 164.15, 163.53, 163.46, 138.97, 133.65, 131.068, 129.11, 123.16,
121.31, 80.73, 73.21, 28.78. TOF-HRMS (m/z) found (calcd.) for C21H25N3O7
(M): [M+Na]+, 454.1588 (454.1590).
Compound 10
Compound 10 was synthesized follow the method as described for compound 8.
MS (modify protein way) (m/z) found (calcd.): 5371.5 (5371.2).
Synthesis for bi-functional molecule for miR-29-b-1
Same as in method described for compound 8 but using 14 MO-29b1 with
compound 7.
MS (modify protein way) (m/z) found (calcd.): 5134.96 (5,135.056).
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Light cleavable bifunctional molecule synthesis

Compound 2 was made from compound 1 following the routine methods.
Compound 4
Compound 3 (1.69 g, 10 mmol) and K2CO3 (1.66 g, 12 mmol) were stirred in DMF
10 min at 90 °C. Propargyl bromide (80 wt. % in toluene, 12 mmol) was added to
above solution. Continue stirring 2h. Extract with Ethyl acetate/ brine. Purify on
silica gel. Yield: 98 %. 1H NMR (Acetone-d6, 300 MHz): 8.18-8.15 (d, J = 9.0 Hz,
1H), 7.56-7.55 (d, J = 1.5 Hz, 1H), 7.11-7.07 (dd, J = 9.0, 2.4 Hz, 1H), 5.03 (d, J=
5.4 Hz, 2H), 4.97-4.96 (d, J= 2.1 Hz, 2H), 4.70-4.66 (t, J= 11.1Hz, 1H), 3.18-3.16
(t, J= 3.6 Hz, 1H). 13C NMR (Acetone-d6, 75 MHz): 162.00, 142.14, 140.47,
127.20, 113.85, 113.02, 77.86, 76.99, 60.95, 56.06. TOF-HRMS (m/z) found
(calcd.) for C10H9NO4 (M): [M+Na]+, 230.0423 (230.0429).
Compound 5
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Compound 4 (1.03 g, 5 mmol) was dropped into a solution containing Compound
4 (1.05 g, 5 mmol) in dry THF under ice bath. Followed by Et3N (5.56 g, 5.5 mmol).
Continue stir 5 hours. Remove the solvent under 30 °C. NH2OH/HCl (0.35 g, 5
mmol) and pyridine (50 mL) were added to the flask and stirred 15 h at 90 °C. Then
remove the solvent and purify on silica gel. Yield: 45%. 1H NMR (Acetone-d6, 300
MHz): 8.57-8.54 (d, J = 7.7 Hz, 1H), 8.41 (s, 1H), 8.29-8.26 (d, J = 9.0 Hz, 1H),
8.03-8.00 (dd, J= 7.8, 0.6 Hz, 1H), 7.47-7.46 (d, J= 2.7 Hz, 1H), 7.25-7.21 (dd, J=
9.0, 2.8 Hz, 1H), 5.85 (s, 2H), 5.00-4.99 (d, J= 2.4 Hz, 2H), 3.22-3.20 (t, J= 4.8 Hz,
1H). 13C NMR (Acetone-d6, 75 MHz): 163.99, 162.82, 161.86, 141.14, 135.59,
135.10, 134.66, 133.29, 129.94, 127.75, 123.36, 115.03, 114.48, 77.66, 77.44,
64.12, 56.28. TOF-HRMS (m/z) found (calcd.) for C19H12N2O8 (M): [M+Na]+,
419.0496 (419.0491).
Compound 7
Compound 5 (0.396 g, 1 mmol) and 1, 8- Diazabicyclo[5.4.0]undec-7-ene (DBU,
0.182 g, 1.2 mmol) stir 10 min in DCM. Compound 6 was added to above solution
and stirred 2 more hours. After reaction is finish. Remove solvent, purify on silica
gel. Yield: 80 %. 1H NMR (CDCl3, 300 MHz): 8.48-8.45 (dd, J = 7.8 Hz, 1H), 8.28
(s, 1H), 8.26-8.23 (d, J = 9.0 Hz, 1H), 8.06-8.03 (d, J= 7.8, Hz, 1H), 7.74-7.71 (d,
J= 9.0 Hz, 1H), 7.37-7.36 (d, J= 2.7 Hz, 1H), 7.24-7.20 (dd, J= 9.2, 2.9 Hz, 1H),
6.72-6.69 (dd, J= 9.0, 5.4 Hz, 1H), 6.52 (d, J= 2.1 Hz, 1H), 6.27 (s, 1H), 5.75 (s,
2H), 5.35 (s, 2H), 5.00-4.99 (d, J= 2.4 Hz, 2H), 3.66-3.64 (t, J= 4.5 Hz, 1H), 3.463.40 (q, J= 20.1 Hz, 4H), 1.15-1.10 (t, J= 13.8 Hz, 6H). 13C NMR (CDCl3, 75 MHz):
163.70, 162.00, 161.32, 160.55, 156.00, 148.15, 140.58, 135.71, 134.61, 134.09,
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132.53, 129.22, 127.86, 126.22, 123.94, 123.22, 115.31, 114.48, 108.71, 105.90,
79.24, 78.09, 75.17, 64.10, 56.35, 43.98, 12.29. TOF-HRMS (m/z) found (calcd.)
for C33H27N3O10 (M): [M+H]+, 626.1782 (626.1775).
Compound 8
Tris[(1-benzyl-1H-1,2,3-triazol-4-yl) methyl] amine (50 nmol), Copper (I) iodide (50
nmol), and Sodium Ascorbate (VcNa) (100 nmol) were mixed together in DMSO.
Followed by Morpholinos (50 nmol) in water, small molecule (100 nmol) in DMSO.
The mixture was shacked and incubated 15h. Separate on HPLC.
8c: MS (modify protein way) (m/z) found (calcd.): 5338.4. (5336.1).
Compound 9
Tris[(1-benzyl-1H-1,2,3-triazol-4-yl) methyl] amine (50 nmol), Copper (I) iodide (50
nmol), and Sodium Ascorbate (VcNa) (100 nmol) were mixed together in DMSO.
Followed by Morpholinos (50 nmol) in water, small molecule (100 nmol) in DMSO.
The mixture was shacked and incubated 15h. Separate on HPLC.
MS (modify protein way) (m/z) found (calcd.): 3995.6 (3996.1).
Bifunctional molecule with fluorophore mimic

Compound 3 was synthesized as described below,

52

5-Hexynoic

acid

(112

mg,

1

mmol),

N-(3-Dimethylaminopropyl)-N′-

ethylcarbodiimide hydrochloride (EDC, 230 mg, 1.2 mmol), and Et3N (202 mg, 2
mmol) were stirred in DCM 30min. Then Compound 2 (374 mg, 1.2 mmol) was
added to above solution. Stir overnight at room temperature. Purify on silica gel.
Rf= 0.4 (Ethyl acetate). Yield: 84 %. 1H NMR (CDCl3, 300 MHz): 8.55-8.53 (dd, J
= 7.5, 0.9 Hz, 1H), 8.39-8.36 (d, J= 8.4 Hz, 1H), 8.22-8.19 (dd, J= 8.4, 0.9 Hz, 1H),
7.64-7.59 (d, J = 15.6 Hz, 1H), 7.12 (s, 1H), 6.50-6.47 (m, 2H), 4.17-4.11 (t, J=
15.0 Hz, 2H), 3.79-3.73 (m, 2H), 3.45-3.42 (m, 2H), 2.47-2.42 (t, J= 14.7 Hz, 2H),
2.26-2.21 (m, 2H), 1.94-1.88 (m, 2H), 1.72-1.69 (m, 2H), 1.47-1.39 (m, 2H), 0.980.93 (t, J= 14.7 Hz, 2H).

13C

NMR (CDCl3, 75 MHz): 175.68, 164.77, 164.32,

150.00, 134.41, 131.13, 129.75, 124.94, 122.83, 120.33, 109.95, 103.21, 83.10,
69.47, 46.55, 39.96, 38.97, 34.87, 30.35, 24.08, 20.45, 17.77, 13.89. TOF-HRMS
(m/z) found (calcd.) for C24H27N3O3 (M): [M+H]+, 406.2129 (406.2131).
Compound 4
Tris[(1-benzyl-1H-1,2,3-triazol-4-yl) methyl]amine (50 nmol), Copper (I) iodide (50
nmol), and Sodium Ascorbate (VcNa) (100 nmol) were mixed together in DMSO.
Followed by Morpholinos (50 nmol) in water, small molecule (100 nmol) in DMSO.
The mixture was shacked and incubated 15h. Separate on HPLC.
4b: MS (modify protein way) (m/z) found (calcd.): 4529.9 (4529.1). 14MO- NXYA
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Pull down assay
We purchased 3’-biotin-labeled 14-mer and 3’-biotin-labelled 25-mer MOs for premiR-21 from Gene-Tools. Total RNAs purified (using Oligotex mRNAs kit from
QIAGEN, Hilden, Germany) from HeLa cells (known to express miR-21) at 37°C.
125 µl of streptavidin beads was taken and washed with washing buffer (10mM
MgCl2, 50mM Tris HCl pH 7.8, 150 mM KCl, 10% Glycerol, 0.1% NP40) twice.
These beads were divided into three equal parts in three 0.5 ml tubes, mixed with
45.4 ul of incubation buffer (10mM MgCl2, 50mM Tris HCl pH 7.8, 150 mM KCl,
10% Glycerol, 0.1% NP40 and 1U/µl RNase inhibitor) and incubated for 15 minutes
at room temperature. To the first and second tubes, each of the 12 µl of 14MObiotin (100 µM) and 25-MO-biotin (100 µM) were added respectively and to the
third tube 12 µl of Biotin only (100 µM) was added. Each tube was incubated with
1/3rd of total RNAs at 37°C for two hours by shaking. Each sample was transferred
to 1.5 ml tube, spinned down and removed supernatant liquid. The beads were
washed three times with 1ml of washing buffer incubating for 5 minutes in each
step at room temperature. Then each tube was washed with 1ml nuclease-free
water before adding 500 µl of 3M Urea and incubate at room temperature with
shaking for one hour. Each sample was centrifugated and taken out the
supernatant (pull downed RNA) carefully and performed ethanol precipitation to
recover total RNA pull downed by each sample.
Alpha-P-32 labelling of pre-miR-21/29b1
The

sequence

of

hsa-pre-miR-21

was

obtained

from

miRbase

(http://www.mirbase.org/). The hsa-pre-miR-21 RNA was in-vitro transcribed from
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template DNA with T7-promoter. DNA template for in-vitro transcription was made
from following primers,
Briefly, forward primer with T7 promoter
5’GAAATTAATACGACTCACTATAGGTGTCGGGTAGCTTATCAGACTGATGTTG
ACTGTTGAATCTCATGGC-3’
And reverse primer
5’-TGTCAGACAGCCCATCGACTGGTGTTGCCATGAGATTCAACAGTCAAC-3’
Similarly, for hsa-pre-miR-29b1
Forward primer with T7 promoter
5’GAAATTAATACGACTCACTATAGGCTTCAGGAAGCTGGTTTCATATGGTGGT
TTAGATTTAAATAGTGATTGTCTA-3’
And reverse primer
5’CCCCCAAGAACACTGATTTCAAATGGTGCTAGACAATCACTATTTAAATCT-3’
0.8 μM each, were subjected to primer extension using Taq polymerase (5 U),
dNTPs (0.2 mM), Taq polymerase buffer (10X) and MgCl2 (1 mM). The reaction
mixture was denatured by heating at 95° C for 30 seconds followed by annealing
at 55°-58° C for 1 minute and primer extension incubation at 68° C for 1 minutes.
This cycle was repeated 30 times before going to final extension at 68° C for 5
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minutes. The hybrid template with T7 promoter was checked using Agrose gel and
used for in vitro transcription with alpha-P32-UTP following manufacturer’s
instructions (Ambion Inc.). The pre-miR-21 substrate was purified by NucAway
Spin Columns (Ambion Inc.) and checked on 16 % denaturing PAGE.
Dicer cleavage inhibition assay
32P-labeled

pre-miRNA was prepared as described earlier. A 10 µL of the reaction

mixture was made by incubating 32P-labeled pre-miR-155 (1 µL, ~20 ng) with Dicer
enzyme (Gen-Lantis) (1 µL) and various concentrations of compounds in buffer
(HEPES 24 mM, NaCl 200 mM, EDTA 0.04 mM, MgCl2 2.5 mM, ATP 1 mM, pH
7.5) at 37 °C for 2.5 h. The reaction was stopped by boiling with equal volume of
Gel Loading Buffer II (Thermo-Fisher Scientific) for 5 min. The non-cleaved premiRNA and the processed miRNA were resolved by 18% denaturing
polyacrylamide gel. The gel was imaged with phosphor imager and analyzed by
quantity one software (Bio-Rad).
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Chapter 3
Optimization of bi-functional regulators and cellular delivery
3.1 Introduction
After showing bi-functional strategy works, we next focused on optimizing each
functional unit of our bi-functional molecules and the cellular delivery. We tested
the effects of additional Dicer inhibition molecules and other ASOs as well as
testing attaching the cell penetrating peptide (CPP) to facilitate the delivery.
3.2 Results and discussions
Optimization of the inhibition unit
Although the N-hydroxyl phthalimide (compound 1) worked as the Dicer inhibition
unit in our bi-functional regulator, we expected that other more potent RNase III
inhibitors (e.g. N-hydroxyimides, diketobutanoates or Flutimides, 4, 5 and 6) may
enhance the activity of bi-functional regulators.1-6 To test this, we synthesized
compound 20 containing a more potent inhibitor and a short linker and conjugated
it to the 12-mer and 14-mer MOs designed for pre-miR-21 to give new bi-functional
regulators (compound 21 and 22) (Scheme 3.1).

Scheme 3.1: Synthesis of bi-functional molecule with more potent inhibitor
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Another strategy to enhance the activity of the Dicer inhibition unit is based on the
crystal structure of Dicer with a double-stranded RNA, which shows two different
cutting sites separated by 17.5 A°, involved in the cleavage of two RNA strands1
(Figure 3.1). We postulated that a Dicer inhibition unit with two inhibitors can
inhibit both the active sites simultaneously giving more potent inhibition. We
designed and synthesized new Dicer inhibition units containing two compounds 1
with different linker lengths (compounds 23 and 24 in Scheme 3.2 and 3.3) and
then tested their Dicer inhibition activity.

Figure 3.1: Crystal structure of Giardia Dicer. (A) Front and side view of Dicer showing
the N-terminal platform domain (blue), the PAZ domain (orange), the connector helix
(red), the RNase IIIa domain (yellow), the RNase IIIb domain (green)1
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Scheme 3.2: Synthesis of two head inhibitor bi-functional regulator with short linker
lengths

Scheme 3.3: Synthesis of two head inhibitor bi-functional regulator with long linker
lengths
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Dicer inhibition assay of optimized inhibitor modules and bifunctional
molecules
We compared the activity of new Dicer inhibition units we synthesized with the
previously used compound 7 by the Dicer cleavage assay. All the new inhibitors
showed enhanced activity as compared to compound 7. The new inhibitor unit with
N-hydroxy imides (compound 20) shows at least four times better activity as
compared to compound 7 and compound 24 with two units of compound 7
connected by a longer linker shows at least 10 times improved activity (Figure
3.2).

Figure 3.2: Dicer cleavage assay for optimized inhibition modules A) and B) Gel
electrophoresis of cleaved and un-cleaved pre-miR-21 C) and D) quantification of pre-miR-21 band
in each lane (3-independent experiments were used to calculate the error bar) for A and B
respectively
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We next tested the activity of bi-functional molecules, compounds 21 and 22, which
contain N-hydroxy imide (compound 20) as the Dicer inhibition unit and compared
to the original bi-functional molecule (compound 12) using the Dicer cleavage
assay. Unexpectedly, we didn’t observe any enhanced activity from new bifunctional regulator with more potent inhibitor unit (Figure 3.3). Furthermore, from
compound 22 and 21 with 14-mer and 12-mer MO respectively also showed similar
activity. In addition, we synthesized bi-functional molecules incorporating
compound 23 and 24 as the inhibition units and tested their activity, which

Figure 3.3:

Dicer cleavage assay for optimized bifunctional molecules A) and B) Gel
electrophoresis of cleaved and un-cleaved pre-miR-21 C) and D) quantification of pre-miR-21 band
in each lane (3-independent experiments were used to calculate the error bar) for A and B
respectively
68

unfortunately did not show any inhibition. Overall, our attempts to improve the
activity of bi-functional molecules by enhancing the activity of Dicer inhibition unit
have not been successful.
Effect of the presence of other RNAs on regulator activity
In the cellular environment, many other RNA species exist that may also bind the
bi-functional regulators due to the imperfect pairing with the MOs used in the bifunctional molecule. This may lead to a reduced activity in cells as we observed
than reflected in the Dicer cleavage assay performed previously, which only
contain the pre-miR-21. To find out whether the presence of other RNAs as in cells
diminishes the activity of our bifunctional molecules, Dicer cleavage assays were
carried out in absence and presence of equivalent total RNA. We observed that
the presence of total RNA has almost no effect on the potency of our bi-functional
molecule on the processing of pre-miR-21 (Figure 3.4), which indicates that the
lack of cellular activity observed previously is likely not due to this possibility.

Figure 3.4: Dicer cleavage assay for bi-functional molecules in presence of total RNA
A) Gel electrophoresis of cleaved and un-cleaved pre-miR-21 B) quantification of pre-miR-21
band in each lane (3-independent experiments were used to calculate the error bar) for A
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Optimization of recognition module
Since the optimization on the Dicer inhibition units did not offer increased activity
of the bi-functional molecules, we next focused on the change of the pre-miRNA
recognition unit. Peptide Nucleic Acids (PNAs), are ASOs with phosphodiester
backbone replaced by N-(2-aminoethyl) glycine units. PNAs have high binding
affinity, are resistant towards enzymatic degradation and easier to synthesize.
However, their neutral backbone cause decreased aqueous solubility.7-20

Figure 3.5: Chemical Structures of DNA (RNA), PNA, and MP-Containing γPNA Units20

Our collaborator, Prof. Danith Ly at Carnegie Mellon University has developed a
new class of PNAs incorporating conformationally preorganized, diethylene glycolcontaining γPNAs which shows enhanced binding affinity with DNA/RNA and water
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Figure 3.6: Synthesis of R-MPγPNA Monomers20

solubility (Figure 3.5 and 3.6).20-22 To test if yPNAs would serve as better
recognition units, we designed 7-nt (FL1), 9-nt (FL2) and 11-nt (FL3) yPNA
oligonucleotides with 3’-azide modification to target the loop region of pre-miR-21.
FL4 (11-mer) was designed as a negative control that cannot recognize pre-miR21.
y-PNA
FL1

ACAACTT

FL2

ACAACTTAG

FL3

ACAACTTAGAG
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FL4

ACTCCATCATCC (negative control)

To find out if these γPNAs bind pre-miR-21, gel shift assays were performed. We

Figure 3.7: Gel Shift assays for γPNA oligonucleotides

A
B

Figure 3.8: Dicer cleavage assay for γPNAs A) Gel electrophoresis of cleaved and un-cleaved
pre-miR-21 and pre-miR-29b1 B) quantification of pre-miR-21 (lane 1-6) and pre-miR-29b1 (lane712) band in each lane (3-independent experiments were used to calculate the error bar) for A
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incubated P32 labelled pre-miR-21 with each γPNA oligonucleotide for 1 h and
analyzed by 15% nondenaturing polyacrylamide gel followed by exposing to
photographic screen and detected using BioRad PMI. Only FL2 (9-mer) and FL3
(11-mer) were found to be able to bind pre-miR-21, whereas the shorter γPNA
oligonucleotide (FL1, 7-mer) and negative control show no binding affinity (Figure
3.7). The Dicer cleavage assays were then performed to determine the inhibitory
activity of γPNAs. We observed that both FL2 and FL3 show certain activity
especially the longer γPNA (FL3) and such inhibition is specific to miR-21 (Figure
3.8). We coupled FL3 N-hydroxy imide (compound 18) using click chemistry to give
a bi-functional molecule FL3-6-R (compound 25). Dicer cleavage inhibition assay
was then carried out with γPNA (FL3) alone or the bi-functional molecule
(compound 25). We observed that the bi-functional molecule indeed has increased
activity than individual units (Figure 3.9).

Figure 3.9: Dicer cleavage assay for γPNA-bifunctional molecule A) Gel electrophoresis
of cleaved and un-cleaved pre-miR-21 B) quantification of pre-miR-21 band in each lane (3independent experiments were used to calculate the error bar) for A
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Comparative inhibition potency of bi-functional molecules
To compare if the bi-functional regulator with yPNA has increased activity than
MO, we calculated the half inhibitory concentration (IC50) of compound 12 (with
N-hydroxy phthalimide inhibitor and 14-me MO), compound 22 (with N-hydroxy
imide and 14-mer MO) and compound 25 (with N-hydroxy imide and yPNA).
Dosage dependent Dicer cleavage assays were carried out for each molecule from
low to high concentrations under similar experimental condition and IC50 value
was obtained for each bifunctional molecule.

Figure 3.10: IC50 value of three most potent bi-functional molecules (three independent
Dicer cleavage inhibition assays were carried out with series dilution for each molecule to
calculate errors)
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IC50 values for compounds 12,22 and 25 were found to be 4.2 µM, 3.5 µM and
0.5 µM (Figure 3.10). From these results, we found that optimizing the pre-miRNA
recognition unit can potentially offer a way to improve the activity of the bifunctional regulators.
Using CPPs to facilitate the cellular delivery of bi-functional molecules
Since Endo-porter had failed to efficiently deliver the bi-functional regulators, we
explored the possibility of incorporating CPPs (oligopeptides typically less than 30
aa residues and net positive charge) to enhance cellular delivery (Table 3.1).23-28
CPP-mediated transport system has been used successfully to deliver cargos (e.g.
ASOs, siRNAs, antibodies, proteins) into the cells (Figure 3.11).27

Figure 3.11: CPP-conjugated molecule delivery across the cell membrane27
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We chose to incorporate the commonly used polyarginine (R8) peptide (Figure
3.12) to deliver our bi-functional molecule. To test if R8 can be used to deliver MO,
we synthesized a fluorescently labeled model bi-functional molecule incorporating
a cysteine (Cys)-conjugated CPP in bifunctional molecule through a disulfide bond
(compound 26, Scheme 3.4). Under the reducing environment in cells, it is
expected that the disulfide bond will be cleaved to give free bifunctional
regulator.29,30
Name

Sequence

Length

Charge

Penetratin

RQIKIWFQNRRMKWKK

16

7(+)

TAT

GRKKRRQRRRPPQ

13

8(+)

Transportin

GWTLNSAGYLLGKINLKALAALAKKIL

27

5(+)

R9 peptide

RRRRRRRRR

9

9(+)

MPG peptide

GALFLGWLGAAGSTMGAPKKKRKV

24

5(+)

KALA peptide

WEAKLAKALAKALAKHLAKALAKALKACEA

30

7(+)

Table 3.1: Most commonly used CPPs23-28

Figure 3.12: CPP (R8) used to deliver bi-functional mimic
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Scheme 3.4: Synthesis of CPP-conjugated fluorophore bi-functional mimic

We examined the cellular delivery of molecule 26 in Hela cells and found that R8
CPP significantly increased the delivery efficiency as compared to the delivery by
Endo-porter (Figure 3.13).
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Figure 3.13: Comparison between cellular delivery by CPP-conjugated system vs Endoporter A) Delivery of molecule by CPP-conjugation at different concentration B) Delivery of
molecule without conjugating CPP and using Endo-porter (all the images were taken after
washing out media)

Synthesis

of

CPP-conjugated

bifunctional

molecule

was

attempted

by

incorporating 3’-azide as well as protected sulfohydryl group at 5’-end in
Morpholino recognition module, but several synthetic problems have been
encountered, including the low purity of modified Morpholino from Gene-Tools.
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3.3 Conclusion
In this chapter, we investigated different strategies to optimize our bifunctional
regulators. We found that incorporating more potent inhibition units did not
increase the potency of bi-functional molecules significantly. One potential reason
may be that since, bifunctional design specifically enriches the Dicer inhibitor unit
at the active site of Dicer associated with targeted miRNAs, the local concentration
of inhibitor might be already very high that even a less potent inhibitor can be
sufficient to inhibit Dicer activity.
However, our attempts to employ a more potent ASO as the pre-miRNA
recognition unit did lead to a more potent bi-functional molecule. We switched MOs
to PNA as the recognition unit and were able to decrease their lengths from 14mer in MO to 11-mer in PNA. The resulting PNA-based bi-functional molecule 25
has shown at least 7-fold increase in potency as compared to other MO-based
bifunctional molecules (compounds 12 and 22).
Finally, we showed that R8 CPP can efficiently deliver a model MO-based bifunctional probe, which can be used for future delivery of the bifunctional regulators
into the cells.
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3.4 Methods
Optimized inhibition modules synthesis

Compound 1
To a stirred solution of 2-(carboxymethyl)-5-hydroxybenzoic acid (1.00 g) in MeOH
(50 mL) was added sulfuric acid (200 μL) dropwise. The mixture was refluxed for
4 h. The solvents were removed by vacuum and the residue was partitioned
between water (50 mL) and ethyl acetate (50 mL). The organic phase was washed
with water (2 X 50 mL) and dried over Na2SO4. The solid was removed by filtration.
The filtrate was vacuumed to remove the solvent. The crude product was purified
by chromatography (Hexane/Ethyl Acetate: 1/1) to give 1 as a yellow oil (0.98 g,
86%). 1 H NMR (300 MHz, DMSO): δ (ppm) 9.76 (s, 1H), 7.31 (d, J = 2.7 Hz, 1H),
7.16 (d, J = 8.4 Hz, 1H), 6.92 (dd, J = 8.4 Hz, 2.7 Hz, 1H), 3.84 (s, 2H), 3.75 (s,
3H), 3.57 (s, 3H).
Compound 2
To a stirred solution of 1 (200 mg, 0.89 mmol) in DMF (5 mL) was added K2CO3
(370 mg) and propargyl bromide (400 mg, 80% in toluene, 2.68 mmol). The
reaction was stirred overnight at 70

o

C. Water (50 mL) was added. The mixture

was extracted with ethyl acetate (2 X 50 mL). The combined organic phase was
washed with brine (3 X 50 mL) and dried over Na2SO4. The solid was filtered off.
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The filtrate was vacuumed to remove the solvent. The residue was further purified
by chromatography (Hexane/Ethyl Acetate: 5/1) to give 2 as a yellow oil (0.195 g,
yield 83%). 1 H NMR (300 MHz, MeOD): δ (ppm) 7.59 (d, J = 2.7 Hz, 1H), 7.24 (d,
J = 8.4 Hz, 1H), 7.15 (dd, J = 8.4 Hz, 2.7 Hz, 1H), 4.77 (d, J = 2.4 Hz, 2H), 3.94 (s,
2H), 3.84 (s, 3H), 3.66 (s, 3H), 2.97 (t, J = 2.4 Hz, 1H). 13 C NMR (300 MHz,
MeOD): δ (ppm) 174.2, 168.6, 158.1, 134.6, 131.8, 130.1, 120.0, 118.1, 79.4, 77.2,
56.8, 52.5, 52.3, 40.3. HRMS (ESI) m/z [M + Na] + 285.0731, calculated for
C14H14O5Na 285.0739
Compound 3
To a solution of 2 (1 eq) in methanol (5 mL) was added water (5 mL) and LiOH·H2O
(4 eq). The reaction was stirred overnight at room temperature. The solvents were
removed by vacuum. The residue was dissolved in water (10 mL). Concentrated
HCl (2 mL) was added to adjust the pH to 1, resulting in white precipitation. The
solid was collected by filtration and dried to give the product as a white solid. 290
mg of 2 was used to produce 187 mg of3 (white solid, yield 72%). 1 H NMR (300
MHz, MeOD): δ (ppm) 7.63 (d, J = 2.7 Hz, 1H), 7.23 (d, J = 8.4 Hz, 1H), 7.14 (dd,
J = 8.4 Hz, 3.0 Hz, 1H), 4.77 (d, J = 2.4 Hz, 2H), 3.95 (s, 2H), 2.96 (t, J = 2.4 Hz,
1H). 13 C NMR (75 MHz, MeOD): δ (ppm) 175.8, 170.0, 157.9, 134.5, 132.4,
130.7, 119.8, 118.4, 79.5, 77.1, 56.8, 40.4. HRMS (ESI) m/z [M + H]+ 233.0451,
calculated for C12H9O5 233.0450.
Compound 4
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A solution of 3 (1 eq) and O-(4-Methoxybenzyl)-hydroxylamine (1.2 eq) in toluene
(180 mL) was refluxed using a Dean-Stark apparatus overnight. The solvent was
removed by vacuum and the residue was purified by column chromatography.
Compound 3 (187 mg) was used to give 4 (174 mg) as a white solid. Elution
solvent: Hexane/Ethyl acetate 2/1; yield 62%. 1 H NMR (300 MHz, CDCl3): δ
(ppm) 7.76 (d, J = 2.1 Hz, 1H), 7.52 (d, J = 8.7 Hz, 2H), 7.22 (m, 2H), 6.90 (d, J =
8.7 Hz, 2H), 5.08 (s, 2H), 4.77 (d, J = 2.1 Hz, 2H), 4.07 (s, 2H), 3.81 (s, 3H), 2.56
(t, J = 2.4 Hz, 1H). 13 C NMR (75 MHz, CDCl3): δ (ppm) 166.0, 161.5, 160.4,
157.2, 131.8, 128.9, 126.4, 126.2, 122.9, 114.0, 112.8, 78.1, 77.8, 76.4, 56.3, 55.4,
37.0. HRMS (ESI) m/z [M + Na]+ 374.1008, calculated for C20H17NNaO5
374.1004.
Compound 5
To a stirred solution of 4 (27 mg, 0.077 mmol) in DCM (1.5 mL) was added TFA
(1.5 mL). The reaction turned to dark red after 4 h. The solvents were removed by
vacuum. The residue was washed with ether (3 X 1.5 mL) to give 5 as a white solid
(15 mg, yield 81%). 1 H NMR (300 MHz, DMSO): δ (ppm) 10.39 (s, 1H), 7.57 (d,
J = 2.4 Hz, 1H), 7.31 (m, 2H), 4.90 (d, J = 2.1 Hz, 2H), 4.18 (s, 2H), 3.60 (t, J = 2.1
Hz, 1H). 13 C NMR (75 MHz, DMSO): δ (ppm) 166.4, 161.5, 156.2, 129.1, 127.5,
126.0, 121.7, 111.9, 78.8, 78.7, 55.7, 36.2. HRMS (ESI) m/z [M + H]+ 232.0616,
calculated for C12H10NO4 232.0610
Compound 6
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Tris[(1-benzyl-1H-1,2,3-triazol-4-yl) methyl] amine (50 nmol), Copper (I) iodide (50
nmol), and Sodium Ascorbate (VcNa) (100 nmol) were mixed together in DMSO.
Followed by Morpholinos (50 nmol) in water, small molecule 5 (100 nmol) in
DMSO. The mixture was shacked and incubated 15h. Separate on HPLC.
6a (with 12 MO-21) = MS (modify protein way) (m/z) found (calcd.): 4516.34
(4516.21).
6b (with 14 MO-21) = MS (modify protein way) (m/z) found (calcd.): 5170.64
(5171.21).
Synthesis of FL3 bi-functional molecule
Tris[(1-benzyl-1H-1,2,3-triazol-4-yl) methyl] amine (50 nmol), Copper (I) iodide (50
nmol), and Sodium Ascorbate (VcNa) (100 nmol) were mixed together in DMSO,
followed by FL3 (50 nmol) in water, small molecule 5 (100 nmol) in DMSO. The
mixture was shacked and incubated 5h, Separated on HPLC to get FL3-6R
bifunctional molecule. MS = m/z found (calcd.) 4695.01 (4696.57)
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Compound 2
To a stirred solution of dimethyl 5-hydroxyisophthalate (DMHIP, 6.3 g, 30 mmol)
and propargyl bromide (80% in toluene, 5.0 g, 33 mmol) in DMF (100 mL) were
added potassium carbonate (4.2 g, 30 mmol). The reaction mixture was stirred at
90℃ about 2h. After the reaction finished, extract with Ethyl acetate/brine.
Combine organic solvent, dry with Na2SO4. Remove the solvent, White solid was
obtained. 1H NMR (CDCl3, 300 MHz): 8.33-8.32 (t, J= 3.0 Hz, 1H), 7.83-7.82 (d,
J = 1.5 Hz, 2H), 4.79-4.78 (d, J= 2.4 Hz, 2H), 3.94 (s, 6H), 2.56-2.54 (t, J= 4.5 Hz,
1H).
Compound 3
LiAlH4 (1.6 g, 42 mmol) and THF (40 mL) was added in a 250-ml flask, the mixture
was kept in ice bath and stirred for 10 min. DMPIP (4.5 g, 20 mmol) in THF (60
mL) was dropped into the flask. The reaction stood in ice bath for 1 h, then at room
temperature for 7 h. After that, the reaction was quenched with water, and the
mixture was filtrated and dried with anhydrous MgSO4. After the removal of solvent
by rotary evaporation, the crude product was crystallized in hexane to give 1,3dihydromethyl-5-proparyloxybenzene (DHMPB) as white crystals. 1H NMR
(Acetone-d6, 500 MHz): 6.96 (s, 1H), 6.89 (s, 2H), 4.76 (d, J = 2.0 Hz, 2H), 4.604.59 (d, J= 5.5 Hz, 4H), 4.32-4.30 (t, J= 10.1 Hz, 2H), 3.05 (s, 1H). TOF-HRMS
(m/z) found (calcd.) for C11H12O3 (M): [M+Na]+, 215.0674 (215.0684).
Compound 4 was made following the routine methods.
Compound 5
84

1H NMR (DMSO-d6, 500 MHz): 11.02 (s, 2H), 8.40-8.38 (d, J= 8.4 Hz, 2H), 8.21
(s, 2H), 7.97-7.96 (d, J = 7.5 Hz, 2H), 7.25 (s, 1H), 7.15 (s, 2H), 5.40 (s, 4H), 4.85
(s, 2H), 3.56 (s, 1H). 13C NMR (CDCl3, 75 MHz): 175.68, 164.77, 164.32, 150.00,
134.41, 131.13, 129.75. TOF-HRMS (m/z) found (calcd.) for C29H18N2O11 (M):
[M+H]+, 571.1009 (571.0989); [M+Na]+, 593.0830 (593.0808).
Compound 6
Tris[(1-benzyl-1H-1,2,3-triazol-4-yl) methyl] amine (50 nmol), Copper (I) iodide (50
nmol), and VcNa (100 nmol) were mixed together in DMSO. Followed by
Morpholinos (50 nmol) in water, small molecule (100 nmol) in DMSO. The mixture
was shacked and incubated 15h. Separate on HPLC.
MS (modify protein way) (m/z) found (calcd.): 5510.8 (5510.1). 14MO-DI-PA

Compound 2
Into a solution of 1 in THF (10 ml), SOCl2 and DMF were added. The reaction was
refluxed for 2 h. The solvent was removed by vacuum and residue was dissolved
in THF (5 ml) and the THF was removed by vacuum to get compound 2.
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Compound 4
Into a solution of 3 in DCM (5 ml), TEA was added. The reaction was cooled to
0°C. A solution of 2 in DCM (5 ml) was then added dropwise. The reaction was
allowed for warming to room temperature and stirred for overnight. The reaction
was washed with H2O (1x10 ml) and dried over Na2So4. The solvent was removed
by vacuum. The residue was purified by chromatography (Hexane: EA=3:1) to give
the product 4 as a white solid (81%).
Compound 5
Into a solution of 4 in DCM, TFA was added. The reaction was stirred for 3 h. the
solvent was removed by vacuum. CH3CN (5 ml) was added to the residue and then
removed by vacuum. It was repeated for 4 times and the residue was then titrated
with Et2O to form white solid. It was collected by filtration and dried over vacuum
to give the product as a white solid (100%). 1H NMR (300 MHz, D2O, δ) 8.22 (m,
1H), 8.12 (d, J = 7.5 Hz, 1H), 7.11 (m, 1H), 7.30 (m, 5H), 5.03 (s, 2H), 4.33 (br,
2H), 3.07 (t, J = 7.2 Hz, 2H), 2.07 (m, 2H). HRMS (ESI) m/z [M+H]+= 355.1290
(M+1)+
Compound 7
Same as in compound 2
Compound 8
Into a solution of 5 and 7 in DCM, TFA was added at 0°C. The reaction was stirred
for 12 h. Then the reaction was diluted with DCM (10 ml) and washed with water
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(3X 10 ml). the organic phase was purified by chromatography (MeOH:
DCM=1:30) to give the product 8 (76%).1H NMR (300 MHz, CDCl3, δ) 8.32 (m,
4H), 7.77 (m, 3H), 7.50 (m, 6H), 7.36 (m, 6H), 7.10 (t, J = 5.7 Hz, 2H), 5.21 (s, 4H),
4.69 (d, J = 2.1 Hz, 2H), 4.46 (t, J = 5.7 Hz, 4H), 3.58 (q, J = 6.0 Hz, 4H), 2.57 (t,
J = 2.1 Hz, 1H), 2.10 (t, J = 6.0 Hz, 4H). HRMS (ESI) m/z [M+H]+ = 893.2669
(M+1)+
Compound 9
Compound 8 was dissolved in CH3SO3H and stirred for 2 h at room temperature.
5ml of water was added to the reaction, and white solid was obtained and collected
by centrifugation and purified by prep-TLC (MeOH: DCM=1:2) to give the product
as a white solid (46%).1H NMR (300 MHz, DMSO, δ) 11.03 (br, 2H), 8.67 (t, J =
4.8 Hz, 2H), 8.34 (m, 2H), 8.19 (t, J = 0.6 Hz, 2H), 7.92 (m, 3H), 7.53 (d, J = 1.2
Hz, 2H), 4.86 (d, J = 2.4 Hz, 2H), 4.39 (t, J = 6.0 Hz, 4H), 3.60 (s, 1H), 3.58 (m,
4H), 2.00 (q, J = 6.0 Hz, 4H). HRMS (ESI) m/z [M+H]+ = 713.1750 (M+1)+
Alpha-P32-UTP labelling of pre-miR-21/29b1
The

sequence

of

hsa-pre-miR-21

was

obtained

from

miRbase

(http://www.mirbase.org/). The hsa-pre-miR-21 RNA was in-vitro transcribed from
template DNA with T7-promoter. DNA template for in-vitro transcription was made
from following primers,
Briefly, forward primer with T7 promoter
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5’GAAATTAATACGACTCACTATAGGTGTCGGGTAGCTTATCAGACTGATGTTG
ACTGTTGAATCTCATGGC-3’
And reverse primer
5’-TGTCAGACAGCCCATCGACTGGTGTTGCCATGAGATTCAACAGTCAAC-3’
Similarly, for hsa-pre-miR-29b1
Forward primer with T7 promoter
5’GAAATTAATACGACTCACTATAGGCTTCAGGAAGCTGGTTTCATATGGTGGT
TTAGATTTAAATAGTGATTGTCTA-3’
And reverse primer
5’CCCCCAAGAACACTGATTTCAAATGGTGCTAGACAATCACTATTTAAATCT-3’
0.8 μM each, were subjected to primer extension using Taq polymerase (5 U),
dNTPs (0.2 mM), Taq polymerase buffer (10X) and MgCl2 (1 mM). The reaction
mixture was denatured by heating at 95° C for 30 seconds followed by annealing
at 55°-58° C for 1 minute and primer extension incubation at 68° C for 1 minutes.
This cycle was repeated 30 times before going to final extension at 68° C for 5
minutes. The hybrid template with T7 promoter was checked using Agrose gel and
used for in vitro transcription with alpha-P32-UTP following manufacturer’s
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instructions (Ambion Inc.). The pre-miR-21 substrate was purified by Nuc-Away
Spin Columns (Ambion Inc.) and checked on 16 % denaturing PAGE.
Dicer cleavage inhibition assay
32P-labeled

pre-miRNA was prepared as described earlier. A 10 µL of the

reaction mixture was made by incubating 32P-labeled pre-miR-155 (1 µL, ~20 ng)
with Dicer enzyme (Gen-Lantis) (1 µL) and various concentrations of compounds
in buffer (HEPES 24 mM, NaCl 200 mM, EDTA 0.04 mM, MgCl2 2.5 mM, ATP 1
mM, pH 7.5) at 37 °C for 2.5 h. The reaction was stopped by boiling with equal
volume of Gel Loading Buffer II (Thermo-Fisher Scientific) for 5 min. The noncleaved pre-miRNA and the processed miRNA were resolved by 18% denaturing
polyacrylamide gel. The gel was imaged with phosphor imager and analyzed by
quantity one software (Bio-Rad).
CPP-conjugated bifunctional mimic with fluorophore synthesis
N-Propargyl-4-amido-1,8-naphthalimide (3) was synthesized according literature
reported procedures*.
*Chemical Communications (Cambridge, United Kingdom), 52(89), 13086-13089;
2016
Compound 1
2,2’-Dipyridyldisulfide (1.21g, 6.0mmol) was dissolved in MeOH (3ml) and AcOH
(0.13ml) was added. To this mixture, a solution of 2-mercaptoethanol (0.3ml,
4.4mmol) in MeOH (3ml) was added dropwise at room temperature over 30 mins
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period under continuous stirring. The reaction mixture was further stirred at room
temperature overnight. The solvent was evaporated and residue was purified by
silica gel column chromatography (EtOAc: Hexane, 1:5 to 1:1), separating the
product as a colorless oily liquid (0.56g, 68.1% yield). 1H NMR (300 MHz, CDCl3)
δ ppm 8.502-8.485(m, 1H), 7.616-7.545(m,1H), 7.409-7.375(m, 1H), 7.1647.119(m, 1H), 5.753(s, 1H), 3.811(t, 2H, J=4.8Hz), 2.959-2.925(m, 2H).
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Compound 4:
To a stirred solution of 3(0.195g, 0.78mmol) and DIPEA (0.300g, 2.3mmol) in dry
dichloromethane(5ml), a phosgene solution (15 wt. % in toluene, 3.64ml, 5.1mmol)
was added. The reaction mixture was stirred at 0°C under inert condition. After 2h,
the excess phosgene was removed from the solution by Argon. Then compound
1(0.3g, 1.6mmol) in dry dichloromethane(2ml) and DMAP (0.244g, 2.0mmol) was
added to the reaction mixture and was stirred over-night. After completion of
reaction (by TLC), the mixture was diluted with EtOAc(10ml), washed twice with
brine solution, dried over sodium sulfate. Filtered and the residue was purified by
column chromatography (EtOAc: CH2Cl2 1:10). Light green solid was purified
(0.36g, 63.1% yield). 1H NMR (300 MHz, CDCl3) δ ppm 8.705(dd, 2H, J=7.2,
12.9Hz), 8.470-8.454(m, 1H), 8.389(d, 1H, J= 8.4Hz), 8.287(d, 1H,J= 8.7Hz),
7.837-7.784(m, 1H), 7.720-7.583(m, 3H), 7.114-7.074(m, 1H), 4.965(d, 2H,
J=2.4Hz), 4.582(t, 2H, J=6.0Hz), 3.185(t, 2H, J=6.0Hz), 2.200(t, 1H, J=2.4Hz).
Compound 5
The compound 4(10ul, 10mM in DMSO) and Morpholino (50ul, 1mM in H2O) were
mixed together. While stirring the solution, the CuSO4·5H2O/Sodium Ascorbate
(VcNa) solution (10ul, 10mM aqueous solution) was added. After stirring the
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mixture at rt for 12 h, the reaction is finished and purified by HPLC to purify the
product as light-yellow solid.
MS= (modified protein way) m/z [M+H]+ = 4750 (M+1)+
Compound 6
The compound 5 (50ul, 0.153mM) was mixed with R8 peptide (8ul, 1mM) in tris
buffer pH 8.0 (50ul, 1M). The solution was stirred at room temperature over-night.
The mixture was purified by HPLC to give 6 as light yellow solid.
Fluorescence images of HeLa cells incubated with Compound 6 solution with
excitation at 359nm,
MO-FL-R8
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Chapter 4
Explore alternative pre-miRNA binder
4.1 Introduction
Although ASOs like MOs or PNAs can be used for our bi-functional molecules,
they have several limitations. To find alternative pre-miRNA binders to be used as

Figure 4.1: Biogenesis of miR-155 and downstream cellular function in breast cancer1
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our recognition unit, we focused on the cyclic peptides, which have been shown to
recognize RNAs with great cell permeability and stability. In this chapter, we tested
the activity and selectivity of a novel cyclic peptide scaffold to target miR-155,
which is a known oncogenic miRNA found to also play roles in cardiovascular
diseases, immunity disorders, inflammation, and viral infections (Figure 4.1).2-16
MiR-155 is upregulated in different breast cancer tissues and used as a
pathological marker, representing tumor condition and survival rate (Table 4.1). It
has been shown that over expression of miR-155 directly promote tumor formation
and pharmacological intervention causes tumor regression. 1 As a result, miR-155
becomes an important therapeutic target.

Table 4.1: miR-155 expression reported in different breast cancer cell types1
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4.2 Results and discussions

Figure 4.2: Synthesis of the thioether bridged one-bead−one-compound macrocyclic γAApeptide library17,18

Our collaborator, Prof. Jianfeng Cai at University of South Florida, has recently
developed one-bead−one-compound thioether bridged macrocyclic γ-AApeptide
combinatorial library containing novel class of the macrocyclic peptidomimetics
(Figure 4.2). The γ-AApeptides have modified peptide backbone with diverse
functional side chains to introduce improved protease resistance, chemo-diversity,
and bioavailability17,18. To explore the possibility of using these peptidomimetics as
a new class of RNA targeting molecules, we screened the macrocyclic yAApeptide library against fluorophore-labelled pre-miR-155.
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Fluorophore labelling of pre-miRNA
Pre-miR-155 was in-vitro transcribed by using cDNA encoding premiR-155
sequence with T7 promoter and an extra G-nucleotide at 5’-end. During in vitro
transcription GMPS (Guanosine mono phosphorothioate) was used along with
normal ATP, UTP, CTP and GTP in 8:1 ratio19. The in vitro transcribed RNA will

Figure 4.3: In vitro transcription followed by fluorophore labelling of pre-miRNA 19,20 and
gel image
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have free thiol group at its 5’-end through the incorporation of GMPS. We then
couple the ATTO 488 fluorophore to this free thiol group by reacting with the
iodoacetamide.20
To confirm the labeling, fluorophore labelled premiRNA-155 was analyzed by 16%
polyacrylamide gel electrophoresis to visualize the fluorescence signal. Then
same gel was also stained with Ethidium Bromide to image RNAs (Figure 4.3).
The results showed that the pre-miRNA-155 was successfully labelled.
Identification of pre-miR-155 binder and test its activity
ATTO-488 labelled pre-miR-155 was screened against a library of macrocyclic
peptidomimetics by Prof. Cai’s group. From the screening, compound 27 was
discovered as a hit for pre-miR-155. After the structure was decoded, compound
27 was resynthesized and subjected to additional assays.

27 (R=H)
Figure 4.4: Structure of library hit screened against pre-miR-155

After we validated the binding using the fluorescence polarization assay, the in
vitro Dicer cleavage assay was carried out to evaluate the activity of compound
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27. We observed that compound 27 can inhibit the cleavage of pre-miR-155 by
Dicer at µM concentrations.

Figure 4.5: Dicer cleavage assay for macrocyclic peptidomimetics (compound 27) A)
Gel electrophoresis of cleaved and un-cleaved pre-miR-155 B) quantification of pre-miR-155
band in each lane (3-independent experiments were used to calculate the error bar) for A

Evaluating targeting selectivity by RNAseq
After we confirmed that compound 27 is active in blocking endogenous miRNA155 production (carried out by another lab member), we investigated the targeting
specificity of this new pre-miR-155 binder by RNAseq and bioinformatics analysis.
We treated MCF-7 cells with compound 27, a commercial antimiR-155 (from IDT)
as a positive control. Non-treated cells were used as the negative control and the
standard for comparison. We performed three replicated experiments for each of
these three conditions (Table 4.2) and total RNA from each experiment was
isolated and sent for RNAseq performed by National Center for Genome
Resources (NCGR).
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Sample Condition

Replicates

A

Mcf7 cells only (non-treated)

A1, A2 and A3

B

Mcf7 cells treated with positive control antimiR-155- B1, B2 and B3
5p (IDT)

C

Mcf7 cells treated with our molecule (Compound 27) C1, C2 and C3

Table 4.2: Description of experimental conditions for RNAseq experiment
The general process for RNAseq and analysis is illustrated in Figure 4.6 and 4.7.
we were interested in finding out differential gene expression caused by
downregulation of miR-155 and by any off-target effect from each treatment. After
using Illumina sequencing platform to sequence all samples with each lane of
1X75nts, adapters were removed from raw read and trimmed depending on
FastQC result. The coverage of sequencing was found to be very good for all
samples with at least 24 million reads per sample and ranging up to 40 million
reads per sample (Figure 4.8).
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Figure 4.6: RNA isolation and library preparation for RNAseq21
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Figure 4.7: Bio-informatics analysis of sequenced reads21
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Figure 4.8: The sequencing coverage for replicates of each samples

Trimmed reads from each sample were aligned with reference human genome
using a tool called GSNAP (Genomic Short-read Nucleotide Alignment Program)22.

Figure 4.9: Alignment metrics for aligned samples
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SAM files (Sequence Alignment Mapping) obtained from each alignment from each
sample was used to get alignment metrics, which showed a good alignment of
reads with our reference genome and similar alignment pattern among replicates
for all samples, ranging from 50% to 90 % (Figure 4.9). Additionally, majority of
aligned reads in our samples were uniquely aligned that means, these reads were
aligned to only one position in reference giving a high confidence on expression
analysis. After making sure our reads are aligned with reference genome well,
each SAM file and reference human genome annotated file (gff file) is used to run
HTseq23 to find out the read count and text file obtained for all the replicates were
combined into a file and followed DESEQ2 work flow to measure differential gene
expression24.
PCA (principal component analysis) plot gives the characteristics of samples
depending on nature of gene expression level. When we plotted PCA, we got a
very clear separation of samples into three groups with replicates of each samples

Figure 4.10: PCA Plot for all samples
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clustered together. This signifies that the gene expression pattern in each replicate
for our samples are comparable or alternatively, there is variation between the
samples but not between the replicates (Figure 4.10).

Figure 4.11: MA plot to compare the differential expression of genes at two different
treatment conditions with cells only as reference (padj ≤0.1)

We used MA plot to compare differential expression of genes in sample B (treated
with antimiR-155, IDT) and C (treated with compound 27) as compared to control
sample A (non-treated Cells only) as reference. In this plot fold change is
calculated from read count value of genes as compared to reference sample gene
count, and then it is transformed into log2 value, where any genes have fold
change value equals to ‘1’, will have ‘0’ log2 value and these genes are not
considered as differentially expressed genes. When log2 transformed values of
fold change for all the genes are plotted against mean of normalized counts, all the
genes with no differential expression will appear at the center (black dots in Figure
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4.11) whereas differentially expressed genes will appear around negative or
positive axis depending on whether these are upregulated or down regulated (red
dots in Figure 4.11). First MA plot in Figure 4.11 (refA Vs B) gives the pattern of
differentially expressed genes of antimiR-155 treated sample as compared to nontreated cell reference whereas second plot (refA vs C) gives the pattern of
differentially expressed genes of compound 27 treated cells as compared to nontreated cell reference. If we look closely this result, it shows a very distinct
characteristic as the antimiR-155 caused more fold change of differentially
expressed genes that are upregulated whereas compound 27 caused more fold
change of differentially expressed genes that are downregulated (Figure 4.11).
Sample

Total number of differentially Positive log2FC Negative Log2FC
expressed genes

(Up-regulated)

(Down regulated)

RefA vs. B

1404

753

651

RefA vs C

1935

1025

910

Table 4.3: Number of Up- and Down-regulated genes in each condition (padj ≤0.05)

It was found that compound 27 caused more genes to change expression as
compared to antimiR-155 (Table 4.3). When we compared the list of differentially
expressed genes in both conditions to each other, 12.8% of the genes are
common. Among upregulated genes 9.5% of the genes are found to be common
whereas in downregulated genes 8.5% of the genes are found to be common
(Figure 4.12)
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Figure 4.12: Comparison of number of differentially expressed genes in both
conditions by similarity (‘refA vs B’ represents differentially expressed genes in
antimiR-155 treated cells and ‘refA vs C’ represents differentially expressed genes
in compound 27 treated cells, untreated cell sample (A) gene expression is used
as reference)

miR-155 target prediction and validated database
To investigate if the genes changing expression upon treatment are miR-155 direct
or downstream targets, we first compile the database of genes that are known or
predicted to be miR-155 targets. We can then compare the RNAseq results with
the database to validate the targeting as well as to identify new miR-155 targets
and investigate the off targets of compound 27 and antimiR-155.
Two in silico prediction software were used to predict miR-155 targets.
“TargetScanHuman7.2” is a prediction software used to predict miRNAs targets by
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the alignment of conserved 6, 7 or 8 nucleotides from the seed region of miRNA
of interest with human 3' UTRs and their orthologs, as defined by UCSC wholegenome alignments as well as detected within open reading frames (ORFs)25,26.
Similarly, “miRDB” is an online database for miRNA target prediction

and

functional annotation. All the targets were predicted using bioinformatics tool called
“MirTarget” and functionality of miRNAs were explored by computational method
and literature mining27,28. Target genes for miR-155 (both -5p and -3p strands)
were predicted using TargetScanHuman7.2 and 2,873 genes were identified at
3’UTR region of human genome. Similarly, miRDB was used to predict miR-155
target genes and 551 genes were identified at 3’ UTR region of human genome.
We further analyzed by comparing these target genes obtained from two different

Figure 4.13: Comparison of miR-155 targets obtained from two different prediction
tools (miR-155_Targetscan represents the targets obtained by using “TargetScanHuman7.2’
tool and miR-155_miRDB represents the targets obtained by using “miRDB”)
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target prediction tools. Out of all predicted genes, 339 genes are common to both
(Figure 4.13)
Furthermore, one more database (miRTarBase7.0) that has information about
updated experimentally validated miRNA target genes was used to find out the list
of genes that are experimentally validated as miRNA targets.29 It includes the
genes that are validated as miRNA target by one or more experimental methods
like qPCR, western blot, reporter assay and/or microarray etc. By using this
database, we prepared the list of genes that are validated experimentally as miR155 targets and 256 genes were found as validated miR-155 genes. When
compared with common predicted genes from earlier two prediction tools, 45
genes were found to be same in both list of genes (Figure 4.14).

Figure 4.14: Comparison between common miRNA targets predicted and experimentally
validated (miR-155_predicted represents the total common genes obtained by using two different
prediction tools in Figure 4.13 and miR-155_validated represents experimentally validated targets
obtained from miRTarBase7.0)
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We will use union of all genes including common (predicted + validated) to
compare with our experimentally upregulated genes.
After generating the database, we selected differentially expressed genes with
positive log2FC values (up-regulated) from each treatment condition and compare
those with miR-155 target genes (predicted + validated) because all direct target
genes of miR-155 should be upregulated with the repression of miR-155.
A good fraction of genes in both treatment conditions were found to be similar to
predicted miR-155 target genes, but majority of genes in each case were not in the

Figure 4.15: Comparison of upregulated genes for both samples with target genes A)
comparison of anti-miR induced upregulated genes with miR-155 target genes B) comparison of
compound 27 induced upregulated genes with miR-155 target genes C) common upregulated genes
between anti-miR induced and compound 27 induced upregulated genes D) comparison between
common upregulated genes with miR-155 target genes
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list of predicted genes. This suggest either these genes are still valid targets but
not been predicted or reported or they might be the secondary and downstream
targets ofmiR-155 target genes. It is also possible that these gene changes are
due to off-target effects that are irrelevant to miR-155 (Figure 4.15).
To understand if there is any functional relationship among the changed genes
and investigate what are the potential off targets, we carried out gene enrichment
and pathway analysis of all the upregulated genes using Cytoscape-ClueGO
software to cluster the functionally similar genes (Figure 4.16 and 4.17).30
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Figure 4.16: Pathway analysis for upregulated genes in anti-miR-155 treated samples A)
Functionally grouped network with terms as nodes linked based on their kappa score level (≥0.3),
where only the label of the most significant term per group is shown. The node size represents the
term enrichment significance. Functionally related groups partially overlap (numbers 1-4 represent
zoomed region) B) Overview chart with functional groups including specific terms for upregulated
genes.

Analyzing the genes that are upregulated upon antimir-155 treatment, we found
the genes can be clustered to several functional groups including defense
response, cell surface receptor signaling pathway, defense response to virus,
response to organic substance, regulation of sequence specific DNA binding
transcription factor, regulation of NF-kappaB (Figure 4.16).
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Figure 4.17: Pathway analysis for upregulated genes in compound 27 treated samples A)
Functionally grouped network with terms as nodes linked based on their kappa score level (≥0.3), where
only the label of the most significant term per group is shown. The node size represents the term
enrichment significance. Functionally related groups partially overlap B) Overview chart with functional
groups including specific terms for upregulated genes.

Analyzing the genes that are upregulated upon compound 27 treatment, we found
the genes can be clustered to several functional groups including sterol
biosynthesis, cytoplasmic vesicle, cytoplasmic part, endomembrane system
organization, single-organism biosynthesis process (Figure 4.17).
By comparing functional cluster of upregulated genes, we found low similarity
between these two treatment conditions (Figure 4.16 and 4.17) and each of these
also have low overlaps with the predicted and validated miR-155 targets (Figure
4.15). All of these results suggest that both antimir-155 and compound 27 have
significant and distinct off targets and effects. We are still in the process of further
analyzing the data using additional bioinformatics tools.
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4.3 Conclusion
We discovered compound 27, to be a new pre-miR-155 binder through a
peptidomimetics library screening, which also show in-vitro and cellular activity.
RNAseq analysis from samples of cells treated with compound 27 and antimir-155
showed that although a certain number of differentially expressed genes in both
treatment conditions matched predicted miR-155 target genes, there are a large
fraction of differentially expressed genes in both conditions showed no direct
connection to miR-155 targets. Further analysis of these genes should give
information regarding the off-target effects of both molecules.
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4.4 Methods
Alpha-P32-UTP labelling of pre-miR-155
The

sequence

of

pre-miR-155

was

obtained

from

miRBase

(http://www.mirbase.org/). The DNA template used for making pre-miR-155 RNA
was generated by PCR primer extension. Briefly, forward primer:
5'GAAATTAATACGACTCACTATAGGCTGTTAATGCTAATCGTGATAGGGGTTT
TTGCCTCCAACTG-3’
and reverse primer:
5'-CTGTTAATGCTAATATGTAGGAGTCAGTTGGAGGCAAAAACCCCTA-3’
0.8 μM of each were subjected to primer extension using Taq polymerase
(Ambion) per the manufacture’s protocol. The extended dsDNA was purified with
NucleoSpin gel and PCR clean-up kit (Macherey-Nagel). The hybrid DNA template
with T7 promoter was used for in vitro transcription using T7 polymerase following
manufacturer’s instructions (New England Biolabs). The reaction mixture was
treated with DNase to digest the template DNA and then extracted with
phenol/chloroform/isoamyl alcohol (25:24:1) (pH 6.7). The RNA was finally
precipitated by ethanol and resuspended in water for storage at -20 °C. Right
before use, the RNA was allowed to refold as follows: RNA was heated to 94 oC
for 2 min and then cooled to 4o C at a rate of 1o C/s.
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Preparation of fluorophore labeled pre-miR-155
5'-GMPS primed pre-miR-155 were first prepared by in vitro transcription as
described above except that 5’-GMPS(Biolog):GTP:ATP:CTP:UTP (8:1:1:1:1 mM)
was used.23 The RNA was purified by phenol/chloroform extraction and ethanol
precipitation. ATTO 488 was then conjugated onto RNA via the 5’ thiol group
following a reported method.24 5'-GMPS primed pre-miR-155 (10 µg) was
dissolved in PBS (1 mL, pH 8.3), followed by the addition of ATTO 488Iodoacetamide for pre-miR-155 and ATTO 590-Iodoacetamide for pre-miR-21 (1.3
equiv) (ATTO-TEC). The reaction was kept in dark at 37 °C for 2 h. The labeled
RNA was purified by phenol/chloroform extraction and ethanol precipitation.
Cell culture
HEK293T and MCF-7 cells were cultured in DMEM medium (Gibco) without
antibiotics, supplemented with 10% FBS and 2 mM GlutaMAX (Life Technologies)
at 37 °C in a humidified atmosphere containing 5% CO2.
Dicer cleavage inhibition assay
32P-labeled

pre-miR-155 was prepared as described earlier. A 10 µL of the reaction

mixture was made by incubating 32P-labeled pre-miR-155 (1 µL, ~20 ng) with Dicer
enzyme (Gen-Lantis) (1 µL) and various concentrations of 24 in buffer (HEPES 24
mM, NaCl 200 mM, EDTA 0.04 mM, MgCl2 2.5 mM, ATP 1 mM, pH 7.5) at 37 °C
for 2.5 h. The reaction was stopped by boiling with equal volume of Gel Loading
Buffer II (ThermoFisher Scientific) for 5 min. The non-cleaved pre-miR-155 and the
processed miR-155 were resolved by 18% denaturing polyacrylamide gel. The gel
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was imaged with phosphor imager and analyzed by quantity one software (Biorad).
MiR-155 inhibition in cell
MCF-7 cell was used for studying the activity of 24 in inhibiting endogenous miR155 in cell. The cells were plated in 24-well plates (500 µL of medium per well) and
grown overnight to 6
̴ 0% confluency. The cells were then treated with 24 (30 µM),
DMSO (0.2% v/v) or anti-miR-155 (30 nM, transfected as described above)
(Integrated DNA Technologies). The cell cultural medium was replaced with fresh
one containing the corresponding small molecule every 24 h. The cells were
harvested after 4-day incubation for the following RT-qPCR, Western blotting, and
flow cytometry analysis.
RNA extraction (RNAseq sample preparation)
Total RNA was extracted using miRNeasy Mini Kit (Qiagen) per the manufacturer’s
protocol for both RT-qPCR and RNAseq. MiRNA reverse transcription reactions
were completed using a Taqman MicroRNA RT Kit (Applied Biosystems) per the
manufacturer’s protocol analyzed by nanodrop and sent for sequencing.
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